I
:‘;>
PIR
Quiz-CMIE
A short
quiz
the end
of each
atrics
in
can
Review.
Credit
be found
article
Use
at
tion to sponsor
ical education
The American
in Pedithe Quiz
Card (bound
into the January
issue) to record
your answers.
diatrics
designates
the Pediatrics
Review
and Education
Program (PREP)
for 56 credit
hours in Category
I of the
Physician’s
Recognition
Award
Each question
has a SINGLE
BEST
ANSWER.
The answers
to the questions
appear
on the
inside front cover of each issue.
Three
AMA
tinuing
Category
medical
of the American
1 con-
ciation.
PREP
education
answers
credit,
record
your
Asso-
the criteria
for
of credit
toward
the
to the American
Academy
of
Pediatrics,
PREP Office,
P0
Box 927, Elk Grove
Village,
IL
(Term
of approval:
beginning
date January
1995. Enduring
materials
are approved
for
60009-0927.
1 year with option
to request
renewal.)
For specific
informa-
To receive
CME
Quiz
Cards
received
after
Lion, please
consult
Office of Continuing
this
Education.
PREP
In addition,
Paediatric
PREP
as one
to demonstrate
tenance
of competence
(MOCOMP).
CPS
AAP
credits
receive
the
PIR
Quiz
the Self-Assessment
ply
Sheet
under
The American
Pediatrics
(AAP)
will
ment
Card
and
Credit
Re-
separate
cover.
individual
Academy
of
is accredited
hours
by the Accreditation
Council
for Continuing
Medical
Educa-
PREP
in
#{149}.
Rciien
I ni.
I(
No.
/2
NAPNAP
l)c
ember
/ VV5
requesting
should
participation
been approved
contact
hours.
and
accreditation
National
proof
Fellows
150
1996 to all mdiqualify.
for
An
a Fellow
Fellow
Edor
must:
a minimum
of 75 credit
through
participation
in
PREP
or PREP:
The
the remaining
hours
(75
hours)
Course,
credit
through
other Academy-sponsored
-approved
CME activities.
AAP
CME
courses;
to the
ACQIP;
Pediatric
UPDATE
Audiocassette
Tape Program:
or other AAP approved
Office.
courses.
verification
of
or
This may include:
AAP
Spring
Session
or Annual
Meeting:
of
for the PREP
Award,
Candidate
contact
submit
CME
To qualify
ucation
of Education.
PREP
has
56 NAPNAP
approved
cally in July
viduals
who
tion. For specific
information,
please
consult
the AOA Depart-
You
Education
Academy
of
accepted through December
31,
1997. A special
note
to PREP
subscribers:
the
Fellows
and Candidate
who earn a minimum
and
#{149}
Earn
group
in-
consult
The AAP PREP
Award
recognizes
is acceptable
for 32 AOA Category 2-B CME hours by the
American
Osteopathic
Associa-
volume
will be
please
directly.
of
Cards from the 1995
Pediatrics
in Review
reviewed
main-
over 3 consecutive
years. The
Award
will be mailed
automati-
the AAFP
Medical
been
approved
for pedia-
For specific
formation,
#{149}
Earn
hours
has
has
method
tricians
and
deadline
will be recorded
in the
year they are received.
Quiz
the Canadian
Society
PREP EDUCATION
AWARD:
hours by the American
Academy of Family
Physicians.
credit
on the 1995 annual
credit
transcript,
Quiz Cards must be
received
by February
28, 1996.
l’eili,,t,,
Medical
AAP PREP Education
Award.
PREP
has been reviewed
and
is acceptable
for 56 Prescribed
on the Pediatrics
in
Quiz Card and send it
Review
meets
56 hours
(CME)
credits
are awarded
per
completed
issue for a yearly
total of 36 CME credits.
To obtain
continuing
medfor physicians.
Academy
of Pe-
.J 7)
I
-
-..
I
CUMULATIVE
Pediatrics
in Review
Volumes
13 (1992),
AUTHOR
14 (1993),
15 (1994),
and
I
r
‘-
INDEX
16 (1995)
A
Alderman,
E. Meller,
13:314
Algranati,
P.S., 13:16
Amin,
S.B., 14:361;
16:349
Andrews,
Arvin,
Audet,
J.S., 15:391
Antonarakis,
S.E.,
13:138
A.M.,
13:107
M., 16:290
B
Baker,
R.B.,
14:361
Baldwin,
H.S.,
16:443
Balistreri,
W.F.,
16:257
Baltimore,
R.S., 15:167
Banez,
G.A.,
14:455;
Barakat,
L.P., 16:419
Baren,
J.M.,
16:229
Barness,
L.A.,
15:321
Berkowitz,
CD.,
13:443;
14:324
Bisett,
T.C.,
13:269
Bithoney,
W.G.,
13:453
Blum,
R.W.,
15:480
Bracikowski,
A.C.,
13:183;
14:433
Bradford,
B.J., 14:281;
16:117
Brent,
D.A.,
14:380
Brickman,
E., 15:16
Batisky, D.L., 16:433
Bauer,
S., 16:130,
168
Bell, B., 16:290
Benaroch,
L., 16:5
Bender,
B., 16:333
Berera, G., 13:391; 14:191
Bergman
D.A., 14:208
Bergman,
I., 15:241
15:5
C
Chesney,
R.W.,
16:101,
Christenson
J.C., 16:62
Cocalis,
MW.,
14:273
Cocores,
J.A., 14:275
Cohen,
M.I., 13:3 14
Coiro,
M.J., 16:306
Coleman,
W.L.,
16:448
Cohn,
A.A.,
15:192
Canty,
D., 16:290
Capute,
A.J., 15:473
Carroll,
J.L., 14:51, 83
Casey,
P.H., 14:4
Cavanaugh
R.M., Jr., 15:485
Chamberlin,
R.W.,
13:64
Chapman,
D.D.,
13:33,
157
Chesney,
P.J., 15:276
137
Conners,
G.P.,
16:37,
Coplan,
J., 16:91
Craig,
C.L.,
14:395
Cron,R.,
16:117
Cross,
J.T., I 6:123
Culbert,
T.P., 14:455;
Custer,
J.R., 14:19
Cutting,
G.R.,
13:138
223
15:5
D
Danilowicz,
D., 16:148
Darville,
T., 15:54
Davis,
J.M.,
13:36
DeAngelis,
C., 13:33, 295;
16:114
Deeb,
D., 16:155
Denny,
F.W., Jr., 15:185
Deutsch,
E.S., 16:17
15:391;
Deutsch,
M., 15:16
Devries,
J.M.,
14:361;
DeWitt,
T.G.,
16:349
Dietz,
W.H.,
14:337
DiLiberti,
Dixon,
Drutz,
J.H.,
Dubowitz,
H., 13:453
Duffy,
L.F., 13:50
Duncan,
C.C.,
14:389
DuPont,
R.L.,
13:381
Durbin,
W.A.,
15:63
Dvorak,
M.D.,
15:201
Dworkin, P.H., 13:16
16:349
13:334
R.H.,
13:391
J.E., 13:125
E
Egan, H., 13:453
Eigen,
H., 15:403
Emans,
J.B., 16:299
Emans
S.J., 14:141
Emery
R.E.,
16:306
Epstein,
L.G.,
16:426
Erickson,
L.C., 14:273
Esterly, N.B., 15:220
Evans,
L.D.,
14:4
Evans,
W.E.,
13:413
F
Falaki,
N.N.,
15:117
Feigin
R.D.,
16:83
Ferry,
P.C., 13:248
Fireman,
P., 16:178
Fischer,
P.R.,
14:95
480
Fiser, D.H.,
14:148,
163
Fisher,
D.A.,
15:227
Fitzwater,
D.S.,
15:102
Flanigan,
T.P., 15:461
Fong, C-T, 16:390
Freeman,
Frieden,
Friedman,
Friedman,
Futterman,
Pediatrics
in Review
J.M.,
13:298
I.J., 16:142
E.M.,
15:495;
S.B., 15:354
D., 15:354
Vol.
16
No.
12
16:155
December
1995
0..:
I
G
Garber,
R.M.,
13:98
Garcia,
J.J.J.,
15:39
Garfunkel,
L.C., 15:369
Gamica,
A., 16:433
Gartner,
L.M.,
15:422
Giardina,
P.J., 13:55
Gigliotti,
F., 16:203
Gilbert,
W.L.,
14:281
Gilbride,
K.E., 16:338
Gittes
E.B., 14:180
Glotzer,
D., 13:461
Gold, M.A.,
15:354
Goldberg,
M.J., 14:395
Goldbloom,
R.B.,
13:183,
Goldman,
D.A.,
13:283
Goldstein,
B., 15:213
Goldstein,
S.L., 16:83
Goodman,
S.I., 15:359
Graham,
E.A.,
15:175
Grant,
L., 13:2 16
Green, J.L., 13:195, 435,
Greene, C.L., 15:359
Greene,
H.L.,
13:185
Greenstein,
M.A.,
13:334
Greer,
F.R., 16:107
Grogan,
D.P., 13:429
312
469;
16:117
H
Haggerty,
R.J., 14:3; 15:3, 253;
Haka-Ikse,
K., 14:401
Hall, C. Breese,
14:335
Hanshaw,
J.B., 16:43
Hardy,
S.C., 15:389
Harper,
G., 15:72
Healy,
G.B.,
13:23
Heiner,
D.C.,
14:226
16:3
Hellerstein,
Hickerson,
5., 14:70,
103
S.L., 16:123
Hilgartner,
M.W.,
Honig,
P.J., 15:266,
327
Honigfeld,
L., 16:273,
311
Hopwood,
N.J., 14:481
Howard,
B.J., 16:448
Howie,
V.M.,
14:320
13:55
Ho,L.,
16:117
Hodgman,
C.H., 16:29
Hogan,
P.A., 14:240
Holmes,
L.B., 13:364
Hulbert,
W.C.
Hurwitz,
S.,
Jr.,
15:272
15:47
I
Ingelfinger,
Irwin CE.,
Isaacson,
JR.,
14:169
Jr., 14:180
Jay,
Jacobs,
R.F., 15:377
Jaskiewicz,
J.A., 15:32
M.S.,
Jellinek,
G.C.,
15:448
M.S.,
16:17
Iseki
M.,
14:226
J
Johnson,
R.L., 16:158,
Jung, F.F., 14:169
16:57
197
K
Kain, Z.N.,
16:2 18
Kamada,
A.K.,
16:266
Kaminer,
S.J., 15:437
Kaplan,
J., 15:391
Kaplan,
S.L., 16:83
Kay, M.H., 14:352
Kearns,
M.E.,
16:57
Kelch,
R.P., 14:481
Kelsch,
R.C.,
14:30
Kendig,
J.W.,
13:262
Kenna
M.A.,
16:69
Kidd, J., 16:433
Klein,
B.R.,
13:127,
422
Klein, J.D., 15:348
Kleinman,
R.E., 14:123
Koenig,
W.J.,
13:391
Kopelman,
A.E.,
16:209
Kreipe,
R.E., 16:370
Krugman,
R., 14:324;
15:394
Krugman,
5., 13:203,
245
Kveton,
iF.,
15:115
L
LaBagnara
S., 16:419
Lake, A.M.,
14:475;
15:78
Lang,
B.A.,
14:194
Lanzkowsky,
L., 13:130
Lanzkowsky,
P., 13:130
Lanzkowsky,
S., 13:130
Lapidus,
C.S., 15:327
Lawrence,
R.A.,
14:265
Lease,
J.G., 13:257
Leopold,
J.C., 15:289
Liptak,G.S.,
13:269;
14:117,
433
Litt, I.F., 16:243
Loughlin,
G.M.,
14:51, 83
Lovejoy,
F.H., Jr., 13:269,
273;
15:127,
151; 16:473
Lynch,
S.K.,
13:435
M
Mathew,
0.P.,
16:209
Mazur,
B., 15:201
McAnarney,
E.R., 15:32
McBride,
J.T., 14:445
McBride,
M.C., 16:386
McCarthy,
D.J., 15:39;
16:223
McCormick,
M.C.,
13:157
Magill,
F.B., 14:191
Magramm,
I., 13:7
Majer,
L. Smith,
14:391
Mandl,
K.D.,
15:151
Marcus, C.L., 14:51
Marino,
E.R., 14:361
Marsh,
J.S., 14:297
Pediatrics
in Review
Vol. 16
No. 12
December
1995
Mclnerny,
T.K.,
16:325
McLeod,
H.L.,
13:413
McMillan,
J.A., 16:283
McQuilken,
P., 16:349
Menna, V.J., 13:113, 363; 14:117,
433; 15:87, 289, 298
Mews,
C. 14:436;
15:233
481
I
I
Meyers,
A., 14:371
Mezoff,
A.G.,
16:257
Mian,
M., 14:401
Milgrom,
H., 16:333
Miller,
H.S., 14:281;
16:37
Miller,
N.S.,
14:275
Miller,
S.!., 15:89
Mooney,
J.F., III, 16:299
Morgan,
Morrison,
Mortimer,
Mueller,
J.P., 13:330: 14:101
S.H., 15:440
E.A., Jr., 13:98
GA.,
15:403
N
Nass,
R.,
13:231
Nazarian, L.F., 13:75, 1 13, 123, 124,
157, 213, 355, 469; 14:67, 207, 215,
299; 15:69, 297, 299: 16:75, 318,
323,
Neilson,
Nield,
Nizet,
I.R.,
Nolan,
T., 14:447
Northrup,
R.S., 15:461
16:35
L.S., 15:369
V., 15:127
363
0
Oberklaid,
Oberlander,
Oblender,
F., 14:447
T.F., 14:313
M., 14:191
Ogden,
J.A., 13:429
O’Gorman,
M., 14:475
Orenstein,
SR.,
13:174
Orlow,
Overall,
S.J., 16:365
iC.,
Jr., 14:251;
16:62
P
Pakula,
L.C.,
13:72:
15:366
Palmer,
F.P., 15:473
Paradise, J.E., 13:2 16
Pascual,
A.G.,
15:201
Pendergrass,
L.B., 16:433
Pemn,
E.C.,
15:354
Pfaffinger,
K., 15:480
Phelps,
D.L.,
16:50
Plotnick,
L., 15:137
Poland, R.L., 14:262, 423; 16:316
Polanecsky, M.M., 13:43, 83
Policastro, A.M., 15:117
Powell
K.R.,
16:163
Powers,
KS.,
15:2 13
Pramanik,
A.K.,
13:163
Prober,
C.G.,
13:107
Putnam,
T.C.,
13:37 1
Q
Quion,
N.,
16:349
R
Rabinowitz,
L.G.,
15:220
Rabinowitz,
R., 15:272
Ramesh,
S., 16:403
Ramos,
AG.,
15:24
Rand,
T.H.,
14:371
Rapin,
I., 14:43
Rappaport,
L.A.,
14:3 13
Rasmussen,J.E.,
13:152; 15:110
Reiff, M.I., 14:455;
15:5
Renshaw,
T.S., 16:458
Rickert,
V.A.,
15:448
Rimar,
S., 16:218
Risser,
W.L.,
14:424
Rivera,
J.A. 14:155
Robertson,
W.O.,
13:33,
Robinson,
T.N.,
14:337
Rome,
E.S., 16:184
Romero,
R., 14:123
Rosen,
F.S., 13:387
Rosengren,
S. Shulman,
Ross, A.J. III, 15:338
Rotta,
A.T.,
15:495
Roy, D.R.,
16:380
Rubenstein,
J.S., 14:489;
Rudolph,
C., 16:5
Ryan, J., 15:289
1 13
13:334
15:204
S
Sahler,
O.J., 13:3; 14:331;
15:3, 337
Saylor,
K.E.,
13:381
Sayre,J.W.,
13:269;
15:211
Schemer,
A.P.,
15:3
Schonberg,
S.K., 13:314
Schowalter,
I.E., 15:384
Schutze,
G.E.,
15:377
Schwartz,
R.H.,
14:101
Schwartz,
S.A.,
16:403
Sears, M.L., 13:127, 422
Sedman,
A.B.,
14:30
Sehgal N., 14:215; 15:391
Sehic,
A., 16:101,
137
Seidel
J., 14:237,
284; 15:157;
16:
229,
482
466
Shackelford,
P.G., 14:291
Shannon, M., 13:295; 15:117
Shapiro,
E.D.,
15:167
Shapiro,
G.G.,
13:403
Sheeran, P.W., 16:37
Sheldon,
C.A.,
16:22
Shusterman,
S., 15:31 1
Siegel,
D.M.,
16:477
Sills, I.N., 15:417
Sills, R.H.,
16:226,
419
Silverman,
E.D.,
14:194
Sinatra,
F.R., 14:436;
15:233
Singalavanija,
S., 16:142
Singer,
H.S., 15:94
Sinkin,
R.A.,
13:36
Sirotnak, A.P., 15:289, 394
Slap, G.B.,
13:43, 83
Smith,
A.L.,
14:11
Smith,
S., 13:435;
14:117
Smith-Ross,
S., 15:400,
433;
311
Solomon,
W.R.,
15:301
Spahn,
J.D., 16:266
Spinelhi,
H.M.,
16:273,
14:473
Stafstrom,
C.E., 16:248
Starke,
J.R., 13:343
Stein,
R.E.K.,
13:224
Stevenson,
R.J., 14:302
Stewart,
C.L., 14:218
Strasburger,
V.C.,
13:144
Pediatrics
in Review
Vol.
16
No.
12
December
1995
I
.
:‘t
.
Stratakis,
C.A.,
Strong,
W.B.,
Sullivan,
16:433
13:379;
15:437;
J.L.,
15:63
Swanson,
H.,
15:39
16:277
T
Taft, L.T., 16:41 1
Taubman
B., 14:155
Tejeda, D.M., 13:469; 15:369, 391
Tina, L.U.,
Tingelstad,
Todd,
J.K.,
14:218
J., 16:347
16:190
Tuchman,
D.N.,
15:24
Tuite,
R.J., 16:223
Turner,
T., 16:155
U
Udall,
IN.,
Jr.,
13:185
V
Vaughan,
V.C., III,
Vinci,
R.J., 15:127
Vadasz,
A.G.,
16:426
Vandeven,
A.M.,
14:141
Vane,
D.W.,
13:25
13:88
Vining,
Virant,
E.P.G.,
13:305
F.S., 13:323
w
Wacksman,
J., 16:22
Wahrman,
i.E.,
15:266
Wald,
E.R., 14:345
Walker,
A., 15:389
Waller
B.R., III, 16:433
Walsh-Kelly,
C.M.,
14:155
Wasserman,
R.C.,
13:4
Watterberg,
K.L.,
Weitzman,
M.,
14:262
13:461
Welliver
Welliver,
J.R., 14:134
R.C.,
14:134
Werner,
M.J.,
14:466
Weston,
Wimmer,
W.L.,
I.E.,
14:240
Jr., 15:255
Wohl,
M.E.B.,
15:192
Woodin,
K.A.,
15:440
Woolf,
A.D.,
l4:4l1;16:473
Wooton,
J., 15:89
Wyatt,
R.J., 15:102
Wyllie,
R., 14:352
Y
Yamauchi,
T.,
14:202;
15:54;
16:123
Yancy,
W.S.,
16:12
Young,
R.S.K.,
14:364
z
Ziegler,
MM.
Pediatrics
in Review
14:302;
15:286
Vol. 16
No. 12
December
1995
483
.:
:.;
,
:. -.
-
-
:
CUMULATIVE
SUBJECT
INDEX
The following
index covers
subjects
in Pediatrics
in Review
in Volumes
13 (1992),
14 (1993),
15 (1994),
and 16 (1995).
Each entry includes
the volume
and page number
of the article
in which the subject
appears.
(abs)=abstract.
Additionally,
the index includes
subjects
addressed
in the Self-Assessment
(SA) Exercise
for 1993, 1994, and 1995. Each entry includes
the question
number
and year in which
the subject
appears.
A
Abdominal
masses,
migraine.
pain,
underachievement,
13:25,
129(abs)
15:94
16:448
cholecystitis,
SA95:#1
Accidental
Accidents,
I 4: 155
chronic
14:67,
in school-age,
SA95:#1
06
functional.
14:67
1-lenoch-Schoenlein
purpura,
I3 :I30
in children.
14:302
intussusception,
irritable
bowel
I 3:397(abs)
I 3:391
syndrome,
management.
16:218
SA95:#1
32
of
ovary,
trauma,
computed
I3:238(abs)
wall, defects,
16:433
Abortion,
I 3: 183
tomography.
in adolescents,
Abruptio
15:32
placentae, 14:1 lfl(abs)
Abscess
peritonsillar, 13:74(abs)
characteristics,
SA95:#256
retropharyngeal,
characteristics,
SA94:#1
76; SA95:#256
SA94:#262
tubo-ovarian,
I 3:216
Absence
seizures,
13:305
Abuse
drugs,
13:314
behavioral
problems,
I 5: 16
failure to thrive, 13:453: 15:39
treatment,
perpetrator,
SA93:#21
sexual,
13:443
conflict
diagnosis
sexuality
vulvovaginitis,
7
resolution,
15:16
of Chlainvdia,
SA94:#1
children,
14:401
14:141
73
fetal effects,
13:364
treatment
of acne,
15:47
Acetaminophen
overdose, 14:411: 15:151
presentation,
SA94:#1 63
treatment,
SA94:#204
Acetylcholine,
in gastrointestinal
disease,
15:389
Achievement
tests,
I 6:338
attentional
disorders,
14:455;
14:263(abs);
clinical
SA95:#65
SA94:#277
Adjustment
Adjustment
Adolescence,
SA93:#161
manifestations,
14:103
metabolic,
SA93:#161
renal tubular,
13:391:
SA93:#222
serum
potassium,
SA95:#20
Acne,
treatment,
15:47; SA95:#49
teratogenic
risks, SA95:#181
#280
Acquired
immunodeficiency
syndrome,
16:283,
290
cat scratch
disease,
15:348
cytomegalovirus,
16:43
immune
system,
14:226
management,
14:371
sexually
transmitted
diseases,
14:
226; 15:461
testing
in infants,
l4:38(abs)
central
Acrodermatitis
causes
chronic
Acyclovir
indications,
14:157
in newborns,
15:485
SA93:#154
physical
disorders,
with
SA93:#1
13:224
medications,
50
concrete
thinking
vs abstract
reasoning, SA95:#21 5
depressant
substances,
13:381
depression/suicide,
I 4:380
eating
disorders,
15:72
examination
of genitalia,
13:272(abs)
laboratory
values,
13:472(abs)
normal
behavior,
SA93:#21
I 3:157:
pelvic
inflammatory
13:2
SA95:#268
risk
disease,
16
factors
SA95:#1
for alcohol
use,
50
substance
abuse,
13:314:
SA93:#31
2
the ‘loner’
and psychologic
problems,
SA95:#1 75
SA95:#233
‘
13:107
Pediatrics
levels,
of death,
compliance
352(abs)
dermatitis,
phosphatase
13:47 1 (abs)
anticipatory
guidance,
cyanosis,
enteropathica,
disorder,
14:380
to death,
16:419
16: 158, 243
alkaline
,
vs atopic
16:203
15:461
13:269
labial,
l5:87(abs);
petechiae,
Adhesions,
14:70
Acidosis,
16:101,
137
electrolyte
abnormalities,
14:251;
21
conjunctivitis,
equilibrium,
15:276
deficiency,
14:226
manifestations,
SA93:#1
diarrhea,
vs
14:320
SA93:#56
Adenopathy,
cervical,
Adenosine
deaminase
immunodeficiency,
Adenovirus
Achondroplasia,
SA93:#1 49
intellectual
outcome,
SA95:#51
Acid-base
balance,
renal mechanisms,
Acrocyanosis,
16:223
Adenoidectomy,
otitis media,
Adenoids,
16:17
Adenoma
sebaceum,
vs acne,
distribution
of lesions,
SA95:#268
Acute
life-threatening
event,
14:383
meningitis.
13:1 l2(abs)
failure,
14: 15 l(abs)
drug abuse,
13:314
learning
disability,
484
313
16:142,
Academic
achievement.
poisoning,
14:41 1
infant walkers,
SA95:#1
SA93:#70
04
in
varicella,
l5:23(abs),
253
(commentary)
Addiction,
13:381
Addison
disease,
1 3:435;
SA94:#288
Adenitis,
cervical,
13:113:
14:263(abs)
evaluation,
SA95:#212
nontuberculous
mycobacteria,
SA94:#221
pneumonia,
16:117
recurrent.
14:67, 313
sexually
transmitted
diseases,
torsion
factors,
Accutane
or recurrent,
differential
risk
27
iFi
Review
‘
Vol.
/6
No.
/2
1)ecember
1995
I
I
Adoption,
Adrenal
pregnancy
insufficiency,
option,
13:435;
cats,
I 3:435;
16:266;
SA94:#288
Adult respiratory
distress
syndrome,
14:163; SA94:#22,
#182
mortality
in, SA94:#22
near-drowning,
14:148
Adulterants
to street drugs.
15:372(abs)
Adverse
reactions,
to penicillin,
16:83
Aeromonas,
diarrhea,
I 3:97(abs)
Afebrile
seizures,
13:305
Affective
illness,
14:380
Agammaglobulinemia,
14:226
infections,
SA93:#273
treatment,
SA93:#252
15:289;
16:5
Aggression
attentional
behavioral
15:366
disorders,
problems,
14:455
13:144;
disabilities,
rivalry,
child
Aging
out, 13:224
Agoraphobia,
15:384
AIDS-see
Acquired
immunodeficiency
Airway
destruction,
15:16
14:19
16:466
obstruction,
SA93:#280
asthma,
I 3:403
evaluation,
SA94:#1 21
Albumin.
edema.
14:70
Alcohol
abuse,
13:314
dependency,
I6:197
depressants,
13:381
poisoning,
14:411;
15:204
use,
13:144;
16:243
genetic
predisposition,
SA95:#28
risk factors,
SA95:#150
Alkaline
phosphatase,
in adolescence,
13:47 l(abs)
Alkalosis,
metabolic
pyloric
stenosis,
15:338;
SA93:#226;
SA94:#85
Allergens,
avoidance,
15:301
Allergic
conjunctivitis,
16:203
contact
dermatitis,
14:240;
disorders,
passive
rhinitis,
Pediatrics
10
in vitro
smoking,
13:323;
in Review
testing,
risk
if breastfed,
uses,
12
December
1995
otitis
15:93
B, 16:123, 363(abs)
Ampicillin,
16:83
I 3:443
sphincter
tone, 14:117
Anaphylactic
reaction.
I 6:178
Anaphylaxis
characteristics,
I 3:387:
SA94:#1
14:436,
48
insects,
13:413
14:246(abs):
14: l52(abs)
treatment,
SA94:#75,
ANA-see
45
I 6:355(abs)
penicillin,
#102
Antinuclear
antibody
Androgen
insensitivity
resistance
therapy,
Anemia
syndrome,
15:39
syndrome.
15:39
pubertal
delay,
I 3:5(abs)
aplastic,
clinical
SA93:#1
76
findings.
autoimmune
hemolytic,
Coombs
test, SA95:#239
cystic
fibrosis,
erythema
Fanconi,
I 3:469
1 3: 183
infectiosum,
16:349
I 2:236(abs)
hemolytic
G6PD
deficiency.
SA93:#224
hereditary
spherocytosis.
SA93:#1 39
aplastic
crisis,
l5:2l2(abs)
characteristics,
SA95:#38
evaluation,
SA95:#239
jaundice/splenomegaly.
15:245(abs)
15:433
SA94:#275
SA93:#23
media,
prophylaxis. 15:377
rash, Epstein-Barr
virus,
15:63
Amphetamine
poisoning. 13:273
use, 13:330: l4:l0l(point-
fissures,
6
pharmacokinetics,
toxicity,
Amniocentesis,
I 3:334
Amniotic
fluid
fetal lung maturity,
SA95:#129
nasopharyngeal
suction,
13:237(abs)
Amoxicillin,
16:83
Anal
Amebic
colitis,
treatment,
SA95:#24
Amenorrhea,
I 3:43; SA94:#1 70
androgen
resistance,
15:39
anorexia,
16:370
imperforate
hymen,
15:495
primary, SA95:#118
treatment,
SA94:#1 70
Aminoglycosides
levels,
16:62; SA94:#41;
SA95:#207
mechanism
of action,
15:440
ototoxicity.
SA94:#192
16:178
No.
16:83
Alzheimer
disease,
15:473
Amanita
phalloides,
poisoning,
14:411
Amantidine,
side effects,
SA93:#133
Amblyopia,
13:7; l5:497(abs)
Ambulatory
Care Quality
Improvement
Program
(ACQIP).
14:208
asthma
exercise,
I 6:273
responses,
16:311
vaccine
administration
exercise,
15:400
responses,
SA95:#34
counterpoint)
SA95:#61
SA93:#1
14:436
overdose,
Amphotericin
skin testing,
SA95:#164
Alopecia
areata,
SA93:#1 02
Alpha- 1-antitrypsin
disease,
493(abs)
Alpha-fetoprotein
prenatal
diagnosis,
13:334
14:444(abs)
SA94:#295
Vol. 16
8
late phase,
SA93:#28
nasal smear,
SA93:#300
penicillin,
14:l52(abs);
pets, SA95:#9
prevention,
I 5:301
SA95:#21
syndrome
emergency,
SA94:#1
#265
Alport
syndrome
characteristics,
SA93:#80
hearing
disorders,
14:43
renal diseases,
14:30;
15:102
ALTE
(acute
life-threatening
event),
14:214
13:72
syndrome,
59,
levels,
Amitriptyline,
in infants.
SA93:#69
insect
stings,
SA93:#21
significance,
learning
sibling
Aggressive
SA93:#1
Aminotransferase
diagnosis,
16:178
egg, in immunizations,
l4:245(abs):
SA95:#18
environmental
controls,
SA95:#9
environmental
triggers,
SA93:#1 87;
SA95:#9
food, SA93:#69
gastrointestinal,
and vomiting,
15:24, 301
l4:336(abs)
insufficiency,
Aganglionosis,
Allergy,
13:312
behavior,
13:312
16:266;
SA94:#288
suppression,
I 6:266
Adrenarche,
premature,
Adrenocortical
15:32
infancy,
15:175
13:379:
cow milk, SA95:#185
diet, SA95:#204
lead poisoning,
13:461
iron
deficiency.
macrocytic,
medical
SA93:#1
record
microcytic,
92
review,
causes,
15:485
15:299
SA95:#130
I 6:356(abs)
newborn,
physiologic.
13:262:
SA93:#160,
#236
thalassemia,
Anger,
stage
13:55
14:380
of grief.
16:4
19
485
I
I
I
Angioedema
allergy,
13:387
Henoch-Schoenlein
purpura,
13:130
Animal
bites
antimicrobial
prophylaxis,
15:377
Pasteurella
infections,
13:394(abs)
Animals,
allergy
prevention,
15:301
Anion
gap, 14:103;
SA93:#161
poisonings,
15:151
renal tubular
acidosis,
13:391
Anismus,
14:447
Ankle injury,
13:429
Ankylosing
spondylitis,
14:1 17
Anorexia
amenorrhea,
13:43;
16:370
congestive
heart failure,
14:351
constipation,
I 5:53(abs)
management,
15:72
Anoxia,
14:148
Anthropometry,
14:492
Antibiotic
administration,
SA93:#1 72
levels,
16:62; SA95:#207,
#222
mechanisms
of action,
15:440
prophylaxis
otitis media,
13:355
sickle cell, 15:l36(abs)
splenectomy,
l5:274(abs)
resistance
patterns,
15:440
Antibody
immunodeficiency,
14:226
Anticholinergic
medicines,
15:389
Anticipatory
guidance,
l5:82(abs),
485
Anticonvulsants,
16:248
afebrile
seizures,
13:305
fetal effects,
13:364
medical
record
review,
13:75
pharmacokinetics,
SA95:#1 77
Anticytoplasmic
antibody
titer,
systemic
lupus erythematosus,
14:194;
SA95:#148
Antidiuretic
hormone
diabetes
insipidus,
15:201
inappropriate
secretion,
14:70;
SA93:#238
Anti-DNA
antibody
titer, systemic
lupus erythematosus,
14:194
Antidotes
to poisonings,
14:411
Antiepileptic
drugs,
13:305;
16:248
pharmacokinetics,
13:413
Antifungal
drugs,
13:152;
16:123,
363(abs)
Antihistamines
anaphylaxis,
13:387
cold urticaria,
15:289
otitis media,
13:23
side effects,
16:333
Anti-inflammatory,
glucocorticoid,
16:266
Antimicrobials,
otitis media,
13:23
486
Antinuclear
antibody
systemic
lupus erythematosus,
14:194;
SA95:#148
Antituberculous
therapy,
13:343
atypical
disease,
I 4:263(abs);
16:223
cervical
adenopathy,
15:276
Antral
web, SA94:#5
Anuria,
14:218
Anxiety,
15:380;
16:29, 57
depressant
substances,
13:381
Aorta,
aneurysm,
SA93:#21
6
Aortic
insufficiency,
rheumatic
fever,
14:272(abs)
Apgar
score,
13:262
components,
SA95:#264
significance,
13:88; SA94:#95
very-low-birthweight
infants,
16:3 16
Aphthous
ulcers,
14:475
Aplastic
anemia,
16:226
Aplastic
crisis
erythema
infectiosum,
13:236(abs)
hereditary
spherocytosis,
I 5:2 12(abs)
Apnea
bradycardia,
14: 100(abs)
disordered
control
of breathing,
14:51
obstructive,
SA95:#55
evaluation,
SA93:#82;
SA95:#83
vs periodic
breathing,
SA93:#62
reflux, 13:174
sleep disorders,
13: 1 l6(abs)
snoring,
14:445
sudden
infant death syndrome,
14:83
Appendicitis
acute,
I 3:49(abs);
14:302
ultrasonography,
13:49(abs)
vs pelvic
inflammatory
disease,
13:216
Apple juice,
chronic
diarrhea,
I 3:399(abs)
Arbovirus
infections,
16:353(abs);
SA94:#231
Arnold-Chiari
disordered
sleep,
1 3: 1 16(abs)
malformation,
15:480;
SA93:#246
Arrhythmias,
15:437;
16:443;
SA93:#20,
#105
drugs for treatment,
16:229
paroxysmal
supraventricular
tachycardia,
14:237
prolonged
QT interval,
13:469;
15:437
Arterial
blood gas, 15:403
Arthralgia,
Campylobacter
infections,
15:117
Arthritis
differential
diagnosis
of,
SA95:#21
8
Henoch-Schoenlein
purpura,
13: 130
juvenile
rheumatoid,
SA93:#233
cardiac
complications,
SA94:#1
13
Lyme disease,
15:167,
2I9(abs);
SA94:#98
pauciarticular,
15:167;
SA93:#233
postinfectious,
SA93:#24;
SA94:#38
psoriatic,
SA94:#27
reactive,
SA94:#38
vs rheumatic
fever, SA93:#1 20
Ascaris
infections,
16:433; SA93:#1 15
Ascites,
14:436
Aseptic
necrosis
of bone,
16:266
Asperger
syndrome,
16: 130, 168
Aspergillosis
allergic
bronchopulmonary,
SA94:#1
46
cystic
fibrosis,
15:192;
immunodeficiency,
14:226
Asphyxia
perinatal,
SA93:#1 04
prenatal,
SA93:#303
seizures,
16:248
Aspiration,
foreign
body,
16:466
Aspirin
overdose,
13:273;
15:151
therapy,
immune
thrombocytopenic
purpura,
SA94:#272
Asplenia,
14:226;
15:377
opportunistic
infections,
SA95:#1 01
Assessment
8-week,
13:88
16-week,
13:88
24-week, 13:88
28-week,
13:88
52-week,
13:88
3-year, 13:88
4-year,
13:88
5-year,
13:88
Asthma,
13:403;
16:273,
311
airway
obstruction,
SA93:#1 83
allergy,
SA93:#187,
#265
beta agonists,
14:489
beta blockers,
14:489
cough,
l6:72(abs)
drugs for acute,
16:229
exercise-induced,
13:474(abs);
SA93:#317;
SA94:#167
diagnosis,
SA95:#270
foreign
body,
15:121(abs)
glucocorticoids,
16:266
late phase,
SA93:#28
management
in school,
14:391
medical
record
review,
13:213,
214
morbidity,
SA94:#1 4
natural
history,
SA95:#217
noncompliance,
medications,
SA95:#1
passive
Pediatrics in Review
92
smoking,
Vol. 16
14:444(abs)
No. 12
December
1995
I
vs tinea
pneumothorax,
13:398(abs)
prophylaxis,
SA95:#1 39
pulmonary
function
tests,
15:403
sinusitis,
14:345
symptoms,
SA93:#29
treatment,
16:266;
SA93:#113,
pedis,
SA95:#247
disease,
13:312
Atopy
atopic
dermatitis,
chronic
cough,
#296
prevention,
side effects,
16:266,
333
triggers,
SA93:#1 87, #265;
SA94:#146
Ataxia, 16:114
cerebral
palsy,
16:41 1
etiology,
SA94:#1
16
Guillain-Barr#{233} syndrome,
13: 1 13
neuroblastoma,
15:391
opsomyoclonus,
15:39 I
telangiectasia,
14:226; SA95:#67
Atelectasis,
15: 150(abs)
Athetoid
cerebral
palsy,
16:411
Athlete’s heart, 13:15 1(abs)
Athletic
injuries,
SA95:#154
use of goggles,
13:422
use of mouthguards,
SA95:#198
Atlantoaxial
instability,
Down
syndrome,
l3:35(abs);
15:473
Atopic
dermatitis, 15:220
characteristics,
SA93:#289
recurrent
impetigo,
SA93:#261
treatment, 15:220; SA93:#126;
SA94:#1 91
vs acrodermatitis
enteropathica,
SA95:#268
SA93:#250;
15:220
I 3:49(abs)
15:301
Atresia
biliary,
14:436;
15:233
bowel,
13:50
duodenal,
15:24
esophageal,
13:50
intestinal,
15:338
vaginal,
13: 129(abs)
Atrial
myxoma,
16:155
tachycardia,
15:437
Atrioventricular
canal,
l4:488(abs)
Attention
deficit
disorder,
16: 12, 325
Attention
deficit
hyperactivity
disorder
age at diagnosis,
SA94:#100;
SA95:#1 95
characteristics,
SA94:#1 54;
SA95:#1
95
evaluation, 14:455
interventions,
15:5
medical
record
review,
16:75
therapy,
SA93:#249;
SA94:#141
side effects,
SA94:#141
Tourette
syndrome,
1 3:37(abs)
Attentional
disorders,
14:455:
16:75
Atypical
mycobacteria,
lymphadenitis,
I 3:371:
14:263(abs);
15:276:
16:223
Atypical
tuberculosis.
I 3:371:
14:263(abs);
15:276;
16:223
Auditory
acuity,
tests, SA93:#310;
SA94:#1 88
evoked
potentials,
13:248
Aura,
migraines,
15:94
Autism,
16:91,
130, 168
associated
disorders,
SA94:#28
infantile,
SA93:#31
8
Autoi mmune
disorders,
immunodeficiency,
14:226
hemolytic
anemia,
13:469;
SA94:#21
thyroiditis,
9
15:227
Automobile
accidents,
l4:244(abs)
Autonomic
nervous
system,
14:489
Autosomal
inheritance,
13:138
Azathioprine,
inflammatory
bowel
disease,
14:475
Azotemia,
14:103;
15:253(abs);
16:101,
137
hemolytic
uremic
syndrome,
14:218
poststreptococcal
glomerulonephritis,
I 6:278(abs)
B
Back pain
management,
spinal cord
Basilar
artery migraine,
15:94
skull fracture,
SA94:#88
Battelle
Developmental
Inventory
Screening
Test,
I 6:338
Battery
ingestion,
14:41 1 ; 16:35
Battle sign, 14:389;
SA94:#88
Bayley
Scales
of Infant
Development,
14:4; 16:338
Beclomethasone,
13:323
Bee sting, SA94:#75
Behavior
diet, SA94:#78
dysfunction,
allergic
disorders,
16: 178
problems, 13:312; 15:366,
367(abs),
448
puberty,
16:243
Behavioral
16:218
lesions,
I 4: 1 17
Back to Basics
antibiotics
: mechanisms
of action,
15:440
autonomic
nervous
system,
14:489
inborn
errors
of metabolism,
16:390
Bacteremia,
14:366(abs)
etiology,
SA93:#1 88
fever in children,
15:127
occult,
SA93:#254
Bacterial
endocarditis,
prophylaxis,
15:311, 377
Bacterial
sepsis,
neutropenia,
SA94:#248
Bacterial vaginosis, 14:141
Bacteriology
laboratory,
16:62
BAL, lead, 13:461
Balance disturbance, 15:369
Barbiturates,
13:381;
SA94:#157
overdose,
13:395(abs)
Barlow
test, 16:299
Barotrauma,
16:209
Pediatrics
in Review
Vol.
16
No.
12
assessment,
1995
11
Beriberi,
13:185
Beta agonists,
I 3:403
overdose,
15:151
side effects,
16:333
Beta-hemolytic
Streptococcus,
rheumatic
fever,
l4:272(abs)
Beta-lactamase
production,
16:62;
SA95:#13
Beta sympathetic
agonists,
I 4:489
blockers,
14:489
Bethanechol,
gastroesophageal
reflux,
13:174,
198(abs)
Bicarbonate,
14:70
Bicycle
helmets,
13:276(abs)
Bile salts, preterm,
14:123
Biliary
atresia,
SA93:#168
Biliary
tract,
cysts,
16:155
Bilious
vomiting,
neonate,
15:338;
14:455
problems,
16:448
Bender
Visual
Motor Gestalt
test.
16:325
Benzodiazepines,
13:381;
SA94:#1
overdose, 15:151
December
seizures.
16:248
status epilepticus,
16:386
Benzoyl
peroxide,
15:47
Bereavement,
16:419:
SA93:#1
57
SA94:#112
Bilirubinemia,
14:436
487
I
. ..
. .-,.
...
.,
Biofeedback,
14:447
forpain, 16:218
Bipolar
depression,
14:380
Birth defects,
13:334
Bites
animal,
13:257,
394(abs):
in adolescents,
SA93:#243
antimicrobial
prophylaxis,
15:377
human,
13:257;
SA93:#179
Biting,
behavior
problems,
15:366
Bladder
dysfunction, 14:1 17
dyssynergia,
16:190
Blastemia,
in leukemia,
16:155
Bleeding
dysfunctional
uterine,
13:43, 83
gastrointestinal,
SA95:#206
hemophilia,
13:183;
16:290
in newborns,
13:163
rectal,
SA93:#294
juvenile
polyp,
SA95:#63
uterine,
SA95:#147
Blended
family,
15:l49(abs)
Blindness, 15:473; l6:77(abs)
cytomegalovirus,
16:43
infant and preschool,
effect on
motor
and
language
skills,
SA95:#31
meningitis,
13:1 12(abs)
retinopathy
of prematurity,
16:50
Blood
clotting,
16:290
coagulation,
16:290
loss, formula
feeding,
l3:36(abs)
transfusions,
in autoimmune
hemolytic anemia, 13:469
Blood
pressure
SA93:#302
measurement,
SA94:#23
newborns,
13:262
school-age
children,
SA95:#53
Blow-out
fracture,
13:422
Body composition,
14:70
Body mass,
13:396(abs)
Bohn nodules,
15:31 1
Bone
age, l4:133(abs)
interpretation,
SA95:#251
lesions,
neurofibromatosis,
14:433
pain, leukemia,
16:155
scan, osteomyelitis,
15:201 ; 16:380
tumor,
13:469
Bone and joint infections,
16:458
Bone marrow
aspirate,
16:349
examination,
16:226
suppression,
16:349
Borrelia
burgdorferi,
Lyme disease,
15:167;
SA95:#57
Botulism,
infantile,
14:117
Bowel
dysfunction,
14:117
training,
14:447
Brachial
plexus
injuries,
13:77(abs)
Brain
electrical activity mapping, 13:248
tumor,
15:94
torticollis,
14:433
Branhamella
catarrhalis,
transmission, 13:283
Breast
disorders,
I 3:74(abs)
self-examination, 13:74(abs)
Breastfeeding,
14:265;
15:321
drugs, SA94:#244
hyperbilirubinemia,
I 5:422
hypernatremia,
15:201
risk of infant allergy,
15:301;
SA93:#69;
SA95:#61
Breast
milk-see
Milk, human
Breathholding,
15:366;
SA94:#169
vs seizures,
SA95:#1
1
Breech
presentation,
l3:237(abs)
Bronchiectasis,
SA93:#31
6
Bronchiolitis,
14:134
Bronchopulmonary
dysplasia,
16:209
characteristics
of, SA94:#266
poor weight
gain, SA93:#1 43;
SA94:#1 40
prognosis,
SA94:#1 65
radiographic findings, SA94:#266
Bronchospasm,
I 3:403
Broselow
tape, 16:229
Bruising
athletics,
14:424
14:215;
SA94:#155,
#207;
SA95:#1 49
coagulation
disorder,
SA95:#149
conditions
that mimic,
14:215,
SA94:#207
causes,
hemorrhagic
disease
of the
newborn,
14:191
Bruxism, 13:16
Buccal
smear,
SA93:#208
Bulimia
nervosa,
15:72;
16:370
Burkitt
lymphoma,
15:63
Burns,
13:257;
16:466
degree,
distinguishing
features,
SA93:#21 2
electrical,
of face, SA93:#158
minor,
treatment,
SA94:#79
C
Caf#{233}
au lait spots,
14:433;
SA93:#283;
SA95:#92
Caffeine,
half-life,
SA94:#32
Calmette-Gu#{233}rin
bacillus,
effect on
tuberculin
test, I 3:343
Caloric
requirements
during
infancy,
SA94:#256
in preterm,
14:123
Calories,
in formulas,
16: 107
Camphor,
13:273
Camp ylobacter
gastroenteritis.
15:117,461
Cancer
bone,
13:49
hepatocellular.
13:203
liver,
13:203,
245
nutritional problems, SA95:#22
thyroid,
14:481
Candida,
allergy,
16:178
Candidal
infection
cutaneous,
13:152
488
dermatitis,
16:142
human
immunodeficiency
virus,
14:371
in immunocompromised,
14:371;
SA93:#34,
#92
in infancy,
SA93:#3
recurrent
oral disease,
SA95:#1 79
treatment,
13:152;
16:123,
363(abs)
vulvovaginitis,
14:141
Cannabis,
14:466
Cannulation,
blood vessels,
I 3:239(abs)
Capillary
hematocrit,
16:356(abs)
Car seats,
l4:244(abs)
Carbamazepine,
13:205;
l5:367(abs)
Carbohydrate
intolerance,
13:437(abs);
14:313
metabolism,
15:359
Carbon
dioxide,
during
sleep,
I 3:472(abs)
Carbon
monoxide,
13:273
Pediatrics
Carboxyhemoglobin,
Cardiac
arrhythmias,
I 3:295
15:437
murmur,
15:490
prolonged
QT interval,
13:469;
15:437
paroxysmal
supraventricular
tachycardia,
14:273
Cardiogenic
shock,
13:358(abs);
16:155, 347
aortic stenosis,
SA93:#129
characteristics,
SA93:#89,
#129
neonatal
sepsis,
SA93:#89
Cardiology,
16:443
Cardiomyopathy
dilated,
14:361
hypertrophic,
14:361;
16:349
Cardiopulmonary
resuscitation,
newborns,
13:36;
15:255;
SA94:#74;
SA95:#183,
#209
Carditis,
rheumatic
fever,
l4:272(abs)
in Review
Vol.
16
No.
12
December
1995
I
.
.,
Care map, medical
record
review
failure
to thrive,
15:69
Caries,
15:311
Carnitine
deficiency,
15:359
Casein
hydrolysates,
15:107
Cat scratch
disease,
15:348;
SA93:#231
differential diagnosis, 13:371;
15:276
Cataracts,
13:7; 16:266
eczema,
15:327
Cathartics,
14:411
Caustics,
14:41 1
CD4 lymphocytes,
14:371
Cefotaxime,
14:11; 15:54
Ceftazidime,
15:54; SA94:#34
Ceftizoxime,
I 5:54
Ceftnaxone,
14:11;
15:54, 440
Celiac
sprue,
SA93:#235
Cell-mediated
immunodeficiency,
14:226
Cellulitis,
I 3:257
orbital,
16:163;
SA94:#72
periorbital,
16:163
preseptal,
16:163
Central
apnea,
14:51
Central
hyperventilation,
SA94:#20
Central
nervous
system
disease,
13:130
disorders,
13:157
systemic
lupus erythematosus,
14: 194
Cephalopelvic
disproportion,
14:1 l6(abs)
Cephalosporins,
15:54, 440
third generation,
SA94:#34
Cerebral
abscess,
16:277
contusion, 15:213
edema,
15:213
hemorrhage,
15:369
herniation, 15:204
Cerebral
palsy,
16:41 1
classification,
SA95:#1 55
prematurity,
SA95:#78
risk factors,
SA95:#243
seizures,
13:305
Cerebrospinal
fluid, 15:241
meningitis, SA93:#85
obstruction,
13:295
pressure,
increased,
15:2
for
13
Cerebrovascular
accidents,
13:379
Cervical
adenopathy,
15:276
injury,
16:28(abs)
spine malformations,
torticollis,
14:433
Cervicitis,
14:180;
SA94:#200
complications,
13:216
Chaperones,
examination
of genitalia,
13:272(abs)
Charcoal,
14:411
Pediatrics in Review
I
.
Vol. 16
No. 12
Chediak
Higashi
syndrome,
14:226
Chelation,
13:55
Chemical
injuries,
eyes, 13:422
Chemoprophylaxis,
15:377;
16:283
Neisseria
meningiditis,
I 3:370(abs);
SA94:#89
Pneumocystis
carinii,
SA94:#1 64
Chemotherapy,
effects
on intestinal
function,
SA94:#234
Chest
compression,
15:255
pain, 16:218, 349
pneumothorax,
I 3:398(abs)
roentgenograms,
I 3: 196(abs);
15: 162(abs)
wall trauma,
14:237
evaluation,
SA95:#240
Chickenpox,
16:283
use of acyclovir,
l5:23(abs),
253 (commentary)
Child abuse, 13:257; 15:213, 394
bone survey, SA95:#141
bruising, 14:215; SA94:#155
coma,
15:204
fractures, 14:215; SA93:#217,
#306;
SA95:#105,
#141
head injury,
SA95:#40
prevention,
13:64
risk factors,
SA95:#76
sexual
abuse,
14:141
Child Behavior
Checklist
(CBCL),
16:338
Child development,
16:338
Child rearing,
15:354
Childhood
asthma, 13:403
depression,
14:380
intoxications,
14:411
poisoning,
14:411
sexual
abuse,
13:443;
14:141
suicide, 14:380
Chiamydia
trachomatis
cervicitis,
treatment
of,
SA93:#225
eye prophylaxis,
14:423
in adolescent,
14:180
infant
characteristics,
SA94:#267
conjunctivitis,
16:203
treatment,
SA94:#1 08;
SA95:#21 1
laboratory
evaluation,
14:251
pneumonia
of infancy,
SA94:#177
sexual
abuse,
SA94:#1 04
perihepatitis,
SA95:#1 97
sexual
abuse,
13:443
Chloramphenicol
in neonates,
SA94:#125
mechanism
of action,
15:440
pharmacokinetics,
13:413
toxicity,
SA93:#31
4
uses, SA93:#314
December
1995
Chlorhexadine,
Choanal
atresia,
13:283
l6:475(abs);
SA93:#25
Cholangitis,
14:436
Cholecystitis,
14: 155, 302
Choledochal
cysts,
14:302;
15:233;
16: 155
Cholelithiasis,
14:313;
Cholestasis
growth
failure,
SA95:#158
neonatal,
15:233;
SA93:#168
Cholesteatoma,
14:320;
SA93:#21
1
hearing
loss, 15:115
Cholesterol,
1 3:47 1(abs)
in milk,
16:107
Chorea,
SA94:#1 31
Chorionic
villus sampling,
13:334
Chromosome
disorders
DiGeorge
syndrome,
1 3: l97(abs)
Klinefelter
syndrome,
I 3:435
Chrondomalacia
patellae,
SA94:#158
Chronic
active
hepatitis,
13:245
cough,
l3:49(abs),
403
granulomatous
disease,
I 4:226
illness,
13:224;
14:380;
16:448
discipline,
SA93:#86
pregnancy
outcome,
I 6:354(abs)
nonspecific
diarrhea,
I 3:397(abs)
pain, 16:29, 218
Chylothorax,
I 6:79(abs)
characteristics,
SA95:#30
Cigarette
smoke,
passive,
l4:444(abs)
Cimetidine,
15:389
Cimetropium
bromide,
irritable
bowel
syndrome,
15:389
Circumcision,
13:163
bleeding,
16:290
Cirrhosis,
14:436
cholestasis
in infancy,
15:233
viral
hepatitis,
I 3:203,
245
Clarithromycin,
mechanism
of action,
15:440
Clavicle
fracture,
13:262
Clavulanic
acid, 16:83
Cleft palate,
15:3 1 1 ; l6:424(abs)
feeding
techniques,
SA95:#223
management,
SA93:#1 78
Clindamycin,
mechanism
of action,
15:440
Clinical
Linguistic
and Auditory
Milestone
Scale (CLAMS),
16:338
Clonidine, 13:381; 15:5
Clostridium
difficile,
15:461;
SA93:#48,
#78
Clotrimazole,
I 3:152
Clotting
factors,
16:290
Clubfoot,
14:395;
Coagulation
disorders,
13:163
bruises,
SA95:#149
congenital,
recurrent
thrombosis,
SA95:#74
489
I
in neonates,
13:163
Cocaine,
15:89
abuse,
14:361
fetal effects,
13:364
overdose, 13:273; 14:361;
SA94:#80
Coccidioidomycosis,
SA95:#244
Cognitive
development,
travel
13:88;
impairment,
history,
l5:367(abs)
I 3:461
problems,
14:4
Coin ingestions,
16:35
Coining,
as a cause of bruising,
14:2 15: SA94:#207
Coin-rubbing, 14:215; SA94:#207
Cold stress, 13:262
“Cold”
urticaria,
13:387
Colds,
transmission,
13:283
Colic,
13:16;
15:321
abdominal pain, 14:302
Colitis,
14:475
Collagen
vascular
disease,
15:127
Colonoscopy,
14:352
Colostrum,
14:265
composition,
SA93:#1
82
Coma
ethanol
ingestion,
15:117
head trauma,
15:2 13
management
of, 15:204;
16:466
neonatal,
metabolic
causes,
SA95:#254
Comedones,
I 5:47
Commentaries
A modern
pediatric
fable,
16:363
A rare and special
privilege,
13: 123
Acyclovir,
15:253
Editor
and editorial
office move,
I3:243
Guess
who’s
going
to medical
school!,
15:3
How to use PJR for renewal
of
certification,
16:3
Immunization
for hepatitis
B
infection,
14:335
‘Lethargic’
and other adjectives,
13:363
Neonatal
hyperbilirubinemia,
15:253
On consulting
and being consulted,
I 3:124
Pediatrics’
in Review
to hold 1996
cover art contest:
works
by
children!, 16:4
Pickles,
pizza,
and PREP,
13:3
PREP CME credits-your
comments
pay off, 15:3
PREParation
for PRCP,
14:331
PREParation
for PRCPupdate,
15:337
‘
490
I
.
‘
Quality
improvement:
doing it
right,
14:207
Screening
for vision
problems
in
pediatric
practice,
13:4
Taking
the record
review
section
of the pediatric
recertification
examination,
15:297
The importance
of Amy Lynn,
15:87
The man who has two watches:
dealing
with discrepancies
in
clinical
guidelines,
16:323
The pediatric
hospital
consultant,
13: 125
The roar behind
the door,
15:21 1
‘The second
new year’
14:3
Then and now, 15:298
We listen to readers’
suggestions,
I 6:3
Common
variable
immunodeficiency.
14:226
immunoglobulin
subclasses,
14:291
Communication,
of preschool
children,
I 5:4 1 2(abs)
Community
programs,
13:64
Compartment
syndrome.
16:290;
‘
ear deformity,
heart disease.
cardiogenic
endocarditis,
myocarditis,
murmurs,
infections,
associated
scoliosis,
syphilis,
Congestive
13:224
92
Comprehensive
services,
13:64
Computed
tomography
abdominal
trauma,
l3:238(abs)
neurodiagnostic
tests, 13:248
splenic
injury,
15:391
Concussions,
14:424;
15:2
1 3;
16:466
Conduct
disorders.
14:380;
SA94:#1 07
Conductive
hearing
loss, 14:43
Condyloma
acuminata
in adolescents,
14:180
perinatal
transmission,
SA95:#21
sexual
abuse,
13:443
treatment,
SA93:#9
Conflict,
I 6:448
divorce,
16:306
parental,
16:306
resolution,
15:16
Congenital
adrenal
hyperplasia,
l4:336(abs)
characteristics,
SA94:#238
laboratory
evaluation,
SA94:#1
deafness,
dislocation,
99
14:43
hip,
16:299
Pediatrics
13:262
heart failure
15:437
cardiomyopathy,
14:361
diagnosis,
SA93:#162;
SA94:#65
signs,
13:33:
14:361
symptoms,
SA95:#104;
#261
Conjunctivitis.
I 6: 163, 203, 477
allergic.
treatment,
SA95:#32,
#171
allergic
vs infectious,
SA95:#171
chlamydial.
treatment,
SA95:#156
neonatal, 14:423; SA94:#108
prevention,
SA95:#1 89
vernal,
16:203
Connors
Rating
Scales,
16:338
Consciousness.
altered
level,
SA95:#1 22
Constipation
encopresis,
14:447
Hirschsprung
disease,
13:25;
16:5
irritable
bowel
syndrome,
I 3:397(abs)
Constitutional
delay
bone age. SA94:#40,
#62
diagnosis.
SA94:#40,
#62
Constitutional
growth
failure,
15: l61(abs)
Consultation
with the specialist
adolescent
social development,
16: 158
allergy,
13:312
anticholinergic
medications
in
gastrointestinal
disease,
I 5:389
ataxia,
16:114
behavior,
13:312
behavior
problems,
15:366
bone marrow
examination,
16:226
cardiac
arrhythmias,
15:437
cerebral
abscess,
16:277
chest trauma
in children,
14:237
coma and altered
consciousness,
I 5:204
congenital
ear deformities,
14:473
congenital
heart disease,
16:277
corrosive
ingestions,
16:473
cryptorchidism,
I 5:272
degenerative
central
nervous
system
disease,
I 6:426
disorders
of the spinal
cord, 14:364
drug abuse, 16:197
enterococcal
infections,
14:202
eye injury,
13:127
SA94:#6
SA95:#1
1
14:297
arrhythmias,
‘
hemophilia,
13:183
Complement
deficiency,
14:226
systemic
lupus erythematosus,
14: 194
Compliance
barriers,
13:224
chronic
physical
disorders,
with medications,
SA94:#298;
14:473
16:277,
443
shock,
I 3:358(abs)
16:148
I 5: 120
15:490;
SA93:#19
16:62
conditions,
SA93:#1
in
Review
Vol.
/6
No.
/2
December
1995
I
I
eye
prophylaxis
infant,
14:423
heart murmurs,
in the newborn
burns,
I 6:473
ingestions,
16:473
Corticosteroid
acne,
15:47
Corticosteroids,
16:266
adrenal
suppression,
SA93:#76
antenatal
administration,
16:209
asthma,
I 3:403
autoimmune
hemolytic
anemia,
13:469
15:490
hoarseness,
16:69
increased
15:241
i ntracranial
ingestion
of coins
pressure,
and
batteries,
16:35
inguinal
hernia
and
hydrocele,
15:286
otitis
dermatitis,
media,
hearing
peripheral
13:23
loss, 15:115
venous
nutrition,
polycythemia
with
15:78
congenital
heart
disease, 13:379
screening
for scoliosis,
14:297
sepsis
in the newborn,
14:262
shock,
16:338
sibling rivalry, 13:72
skull fractures
in infancy
and
childhood. 14:389
snoring,
14:445
stabilization
of the very-lowbirthweight
infant,
16:316
status epilepticus,
16:386
unknown
poisoning,
13:273
uveitis,
I 3:354(abs)
Cover
test,
Cow milk.
16:477
vascular
Consumptive
Contact
dermatitis,
access,
15:157
coagulopathy,
14:240:
I 3:269
anemia,
SA94:#110,
#207
SA93:#239;
Pediatrics
07
SA95:#191
14:445
SA94:#16
13:422
in Review
Vol.
/6
No.
protein
Coxa
allergy,
valgus,
14:395
/2
December
/995
Bordetella
14:123
of, SA95:#87
16:62
pertussis,
16:62
C’ampvlohacter,
gonococci,
16:62
microbiology.
16:62
throat,
16:62
urine,
16:190
Cupping,
as a cause of bruising,
14:215:
SA94:#207
Cushing
syndrome, SA93:#122
tumor,
14:169
Custody,
joint legal.
16:306
Cyanosis
blood gases, SA93:#256,
#290
central
vs acrocyanosis,
SA93:#70
congenital
heart disease,
16:155.
277
newborn,
l5:l60(abs);
16:155
Cyanotic
heart disease,
13:379;
15: 160(abs);
SA93:#51
Cyclitis,
16:477
Cyclosporin
A, 14:475
Cyst, thyroglossal
duct, SA95:#69
Cystic
fibrosis,
I 5:192
antibiotic
15:175
SA94:#260
#266
SA95:#1
13:7
Cricothyroidotomy,
16:466
Crohn
disease,
14:352,
475
growth
failure,
SA95:#66
treatment.
SA93:#1 6
Cromolyn
sodium
asthma,
13:403;
SA95:#139
nasal,
13:323
Cross-infection,
13:283
Crotamiton, 15:110; l6:336(abs)
Croup.
14:19
diagnosis, SA93:#280
intubation,
SA94:#133
treatment.
16:229:
SA94:#114
Crying.
13:16
Cryotherapy,
retinopathy
of
prematurity,
16:50
Cryptococcosis,
16:123
Cryptorchidism,
15:272
age for surgery,
SA95:#275
disordered sleep, 13:11 6(abs),
473(abs)
electrocardiographic
criteria,
hypoxia.
snoring,
Corneal
abrasion.
injuries,
Corrosive
strabismus,
14:265
varus,
14:395
Coxsackievirus,
14:251;
SA93:#282
Crack
cocaine,
15:89
Cranial
ultrasonography,
13:248
Craniosynostosis,
I 6: 1 15(abs):
SA93:#1 77
management,
SA95:#238
Creatine
kinase,
16:437(abs)
in rhabdomyolysis,
15:495
Creatinine,
variation
with age.
lenses,
13:422
Contaminants
to street drugs,
15:372(abs)
Contraception
adolescent
pregnancy.
15:32
pelvic
inflammatory
disease,
13:2 16
postcoital,
SA94:#53
risks, SA93:#293;
SA94:#290
Contraction
stress test, SA93:#30
Conversion
reaction,
16:29
Convulsions,
afebrile,
13:305
Coordination,
13:224
Coping with death, 16:419
Copper
deficiency,
l6:352(abs)
requirement.
preterm.
14:123
Cor pulmonale
bronchopulmonary
dysplasia,
SA94:#165,
15:327
side effects,
16:333;
SA95:#42
Cortisone, 16:473
Cosleeping,
SA93:#253
Cough
as a sign of abdominal
process,
15:289
asthma,
16:72(abs)
chronic,
16:72(abs);
SA93:#29
congestive
heart failure,
14:36 I
medicine,
14:264(abs)
pertussis,
l3:438(abs);
16:37,
72(abs)
psychogenic,
l6:72(abs)
sinusitis,
14:345
Coumarin,
interactions
with rifampin,
differential
diagnosis
Culture
blood,
16:62,
148
therapy.
SA93:#257
carbohydrate
metabolism,
I 3:278(abs)
decreased
height
and weight,
I 3:73(abs)
disordered
sleep.
13:1 l6(abs)
edema,
13:183
extrapulmonary
complications,
SA95:#269
intestinal
obstruction,
15:338
liver disease, 14:436; 15:233
nasal polyps,
SA93:#245,
#287
neonatal
manifestations,
SA94:#1
pulmonary
function,
15:403
sinusitis,
14:345:
SA95:#124
treatment,
SA93:#257
vitamin
E deficiency.
SA94:#286
vitamin
supplementation.
I 3:185
Cystinosis
associated
conditions,
SA94:#218
ophthalmologic
manifestations,
SA93:#1 08
Cystitis
diagnosis,
SA94:#1 38
Cystourethrography,
voiding,
l3:279(abs);
37
16:22
Cytomegalovirus
infection,
I 6:43
acquired
immunodeficiency
syndrome,
14:371;
16:43
acquisition,
SA93:#260
congenital,
manifestations,
SA93:#1
human
milk,
transmission,
1
SA93:#260
13:283
491
I
1
#{231}.
:..ii:.
.
..
#{149}1
.
%..
D
Dactylitis,
SA95:#1
sickle
cell
disease,
9
Day care
chemoprophylaxis,
I 3:354(abs),
370(abs)
diarrhea,
15:461
transmission
of infections,
13:283;
SA94:#253
Deafness, 14:43; 15:115; 16:91
congenital,
SA93:#1 56
cytomegalovirus,
16:43
meningitis,
14:11;
SA95:#56
osteogenesis
imperfecta.
14:215
Death
causes
in adolescents,
SA93:#1
54
children’s
reactions,
16:419;
SA93:#111;
SA94:#151,
#198
from auto accidents,
14:244(abs)
from drowning,
SA93:#35
Decongestants,
13:23
Decubitus
radiographs.
SA94:#81
Degenerative
disease
of nervous
system,
characteristics,
SA95:#144
Dehydration,
14:103
hypernatremic,
15:201
diabetes
insipidus,
15:201
manifestations,
SA94:#241
neurologic
effects,
SA93:#268
hypertonic,
16:304
hyponatremic
manifestations,
SA94:#225;
SA95:#235
isotonic,
16:304
Delinquency,
I4:2 14(abs)
in adolescence,
16:12
Denial,
stage of grief,
16:4 19
Dental
defects,
cleft palate,
l6:424(abs)
eruption,
delayed,
SA94:#130
Dentistry,
15:311
Denver
Develomental
Screening
Test,
16:338
Depressants,
13:381
Depression,
14:380;
SA94:#181
drug abuse,
13:3 14
in adolescence,
15:485
learning
disabilities,
14:21 4(abs)
migraine,
15:94
Dermatitis
atopic,
15:220,
327; 16:178;
SA93:#250,
#261, #289
contact,
14:240;
SA94:#110,
#207
diaper, 16:142
seborrheic, 16:142
Dermatomyositis,
SA94:#1
73
laboratory
evaluation,
SA95:#15
Dermoid
cysts,
13:371
Desensitization,
13:387
Desferroxamine,
13:55
492
Desmopressin
(DDAVP),
side
SA95:#205
Development
Bayley
scales,
14:4; 16:338
cognitive,
16:243;
SA93:#33,
#213; SA95:#227
fine motor,
SA93:#136
gross
motor,
mental
effects,
#186,
SA95:#1
retardation,
SA94:#51
in adolescence,
16:158
in infancy,
SA93:#286
intelligence
language,
#55
causes
quotients,
15:4l2(abs);
of delay,
SA93:#286
SA93:#33,
SA95:#169
24 months,
SA95:#81
plateau
or regression
in central
nervous
system disorders,
I 3:157
psychological,
16:243
pubertal,
16:243
reading,
SA93:#33
school
readiness,
14:4
screening
tests,
SA95:#262
toilet training,
SA93:#299
writing,
SA93:#207
Developmental
delay,
degenerative
central
nervous
system
disease,
16:426
disabilities,
15:473;
16:130,
168
dislocation
of the hip, 16:299
language
delay,
16:91
problems,
16:448
sequelae,
seizures,
16:248
Test of Visual
Motor
Integration,
16:325
testing,
16:338
Dextrostix,
I 3:262
Diabetes
insipidus
laboratory
evaluation,
SA95#26
nephrogenic,
15:201
osmolality,
SA95:#26
Diabetes
mellitus,
I 5:137
cystic
fibrosis,
I 3:278(abs);
15:192
fetal effects,
13:364
maternal,
effect on newborn,
SA95:#1
0
recombinant
insulin,
SA93:#227
Diabetic
ketoacidosis,
16:304
(pointcounterpoint)
Dialysis,
renal,
16:101,
137
Diapers,
16:142
Diarrhea,
15:461
acrodermatitis
enteropathica,
I 3:157
anticholinergic
medications,
15:389
antimicrobial
prophylaxis,
15:377
bloody,
I 3:97(abs)
Campylobacter
jejuni, SA93:#1
93,
#277
chronic,
irritable
SA93:#191;
bowel,
SA94:#174
l3:397(abs)
Pediatrics
nonspecific,
1 3:399(abs)
Clostridium
difficile
toxin,
SA93:#291
dehydration,
14:103
giardiasis,
14:284
inflammatory
bowel disease,
14:475
intraluminal
nutrition,
14:3 12(abs)
laboratory
evaluation,
14:251
lactose
intolerance,
l3:437(abs)
oral rehydration,
SA93:#291;
SA94:#1 71
predisposing
conditions,
SA94:#1
95
transmission,
13:283
tropical
areas,
14:95
Diary, in diagnosing
migraine,
Diazepam
in human
rectal
milk,
13:4
16:318
13
administration,
13:413
treatment
of febrile
seizures,
13:298
Dideoxyinosine,
human
immunodeficiency
virus,
14:371
Diet, 13:312
attention
deficit
disorder,
SA95:#241
behavior,
SA94:#78;
SA95:#1
36
chronic
diarrhea,
I 3:399(abs)
failure
to thrive,
SA95:#136
Dieting,
16:370
DiGeorge
syndrome,
I 3: l97(abs)
immunodeficiency,
14:226
Digestion,
and low birthweight,
14:123
Digoxin,
13:413;
SA93:#119
Diphenhydramine,
treatment
of
movement
disorder,
15:391
Diphtheria-tetanus
toxoids
with
pertussis
immunization,
16:37
reactions
to vaccine,
SA93:#201
Diplegia,
prematurity,
SA95:#78
Dipstick
test, 14:30
Disability,
physical
disorders,
13:224
parental
stress,
SA95:#140
Discharge
plans, for newborns,
13:262
Discipline,
16:448
Diskitis,
16:380,
458
Disqualification,
sports,
Disseminated
intravascular
coagulation
infants,
13:163
sepsis,
13:269
Diuretic
therapy
complications,
effects
SA94:#1
on electrolytes,
SA95:#1
14:424
09
SA93:#202;
74
nephrotic
syndrome,
14:30
Divorce,
SA94:#12,
#172
blended
family,
15: l49(abs)
effects
on children,
16:306
in Review
Vol.
/6
No.
/2
December
1995
I
I
Dizziness,
15:369
DMSA
treatment,
lead toxicity,
13:461
Dolls,
anatomically
correct,
I 3:443
Donor
blood,
laboratory
evaluation,
hypoalbuminemia,
SA95:#231
theophylline,
SA93:#21
9
screening,
urine, SA93:#12
testing,
13:314
toxicity
acetaminophen,
SA94:#1 63
vancomycin,
I 6:357(abs)
treatment
programs,
I 3:314
Drug abuse,
13:314
cocaine,
15:89
dependence,
SA95:#248
hallucinogens,
SA93:#84
sexually
transmitted
diseases,
I 5:42(abs)
I 5:246(abs)
Dopamine,
14:489
blockers,
SA93:#204
Down
syndrome
atlantoaxial
instability
in,
I 3:35(abs)
cardiac
disease,
14:488(abs);
SA94:#206
characteristics,
SA94:#1 68
duodenal
atresia,
SA95:#37
intellectual
outcome,
I 5:473;
treatment,
Drugs
SA95:#85
hypersensitivity,
in human
I 6:229
Dyspepsia,
16:229
14:265
interactions,
Dysplasias,
SA93:#275
sedatives,
16:229
steady
state, SA93:#7
testing,
in urine, SA93:#12
theophylline,
half-life
of, SA93:#7
Duane
syndrome,
13:7
Duchenne
muscular
dystrophy
complications,
SA95:#1 2
advocacy
14:313
Dysplasia,
developmental
hips, 16:299
milk,
phenobarbitol,
15:338
ulcers,
16:257
Duplication
of intestine,
13:50
Dust mites, management,
SA93:#187
Dysarthria,
16:91
Dysentery,
15:461
Dysfunctional
uterine
bleeding
evaluation,
SA94:#36,
#213
treatment,
SA95:#147
Dyslexia,
13:231:
14:455
Dysmenorrhea,
I 3:83
following
pelvic
inflammatory
disease, 13:216
Dysmorphology,
I 3:364
SA95:#284
13:387
ingestion,
phenobarbitol,
SA93:#112
interactions,
13:113
prevention
and public
initiatives,
13:314
-protein
binding
stenosis,
anticonvulsants,
16:229;
SA93:#274
effects
on learning,
SA93:#301
elimination,
in sick newborns,
emergency,
SA94:#228
SA93:#153;
inheritance,
SA94:#26
Duck embryo
vaccine,
rabies,
I 4:280(abs)
Dunking
burns,
SA94:#52
Duodenal
atresia,
SA95:#37
16:197
analgesics,
prenatal
diagnosis,
I 3:334
risk of leukemia,
16:155
Drowning,
14:148
mortality,
SA93:#35
near, 14:148
prevention,
SA95:#1 31
Drug
dependence,
13:381
dosages,
16:229
fever,
15:127
diagnosis,
of the hip,
16:458
bronchopulmonary-see
Bronchopulmonary
dysplasia
Dysthymia,
14:380
Dysuria,
SA94:#138
sexual
abuse,
13:443
sexually
transmitted
diseases,
SA95:#1
urinary
32
tract
infection,
16:190
E
Ear
malformations,
14:473;
SA93:#142
Early Language
Milestone
(ELMS),
16:338
Early Screening
Inventory
16:338
Eating
disorders,
16:370
EDTA,
penicillamine,
Education
alternative
placement,
Scale
SA95:#1
Pediatrics
iii Review
SA93:#229;
No.
12
23;
SA95:#1
14
Act
SA95:#43
Effusion
middle
ear, SA94:#220
subdural,
in meningitis,
SA95:#265
Egg allergy,
in immunizations,
14:245(abs);
SA95:#18
Ehlers-Danlos
syndrome,
characteristics,
SA95:#1
17
Elbow,
dislocation,
SA93:#2
Electrocardiography,
in cor
pulmonale,
13:47 1(abs);
SA93:#239
Electroencephalography,
16
SA93:#1
14
Education
of the Handicapped
Amendment
(PL99-457),
14:70
Vol.
neonatal
Electrolyte
grade retention,
SA95:#114
mainstreaming,
SA95:#1
14
Education
for All Handicapped
Children
Act (PL94-142),
(ESI),
anorexia,
15:72
Echolalia,
16:91,
130, 168
Ectopic
pregnancy
abdominal
pain, 14:302
pelvic
inflammatory
disease,
14: 180
Eczema,
15:220,
327
bacterial
superinfection,
SA95:#84
characteristics,
SA93:#289
treatment,
SA93:#126;
SA94:#191
Edema
cerebral,
16:304
cystic
fibrosis,
13:183
hypoproteinemia,
I 3:183;
SA94:#302
nephrotic
syndrome,
14:30
physiology,
13:461
December
1995
13:248
seizures,
16:248
management,
diabetic
ketoacidosis,
16:304
(point-
counterpoint)
Electrolytes,
14:70
status epilepticus,
SA93:#15
ELISA
test
allergy,
16:178
human
immunodeficiency
virus,
I 4:38(abs)
infection,
16:62
Emergency
care,
drugs,
Emetics,
Emotional
16:306
Empyema,
16:466
16:229
SA94:#1 44
development
after
divorce,
I 6:79(abs)
Encephalitis
arbovirus,
l6:353(abs)
characteristics,
SA93:#83
enterovirus,
SA93:#230
herpes,
13:107
measles,
SA93:#240
493
42;
.
::
.
,
,,
#{149}.
(:
neurodiagnostic
Encephalopathy
hepatitis,
.
testing,
SA94:#37
14:436
human
immunodeficiency
virus,
14:371
Encopresis,
14:447
Endocardial
cushion
defect.
Down
syndrome.
I 4:488(abs)
Endocarditis,
16:148
pathophysiology.
SA95:#1 78
prophylaxis.
15:311,
377
risk factors,
SA95:#178
subacute,
16:148;
SA94:#239;
SA95:#285
unknown
fever,
15:127
Endometriosis.
I 3:83
Endometritis.
13:216
Endoscopy
gastrointestinal
bleeding,
14:352
laryngeal
disorders,
16:37. 69
Endotracheal
extubation.
16:69
intubation,
15:255
Energy
requirements
in infancy,
SA94:#256
preterm
infant,
14:123
surface
area. SA95:#202
Enteral
nutrition,
15:78, 8l(abs)
Enierohius
infection,
I 6:247(abs)
diagnosis,
SA95:#123
treatment.
Enterococcal
Enterocolitis.
Enterotoxigenic
SA95:#1 23
inl’ections,
I 4:202
16:5
E c’oli infections,
petechiae.
13:269
5
associated
conditions,
management.
nocturnal
primary.
secondary,
pharmacologic
Epilepsy.
SA94:#60
Erythroblastosis.
febrile
infantile
medical
treatment.
Epinephrine.
Escherichia
Epiphysis
I 3:157:
16:458
SA95:#161
treatment.
SA95:#205
13:461
16:62
16:163
Eustachian
tube
balance
otitis
Ewing
media,
sarcoma,
15:369
SA95:#47
I 3:469
surgical.
atypical
mycobacteria,
I 4:263(abs)
Exercise
-induced
asthma.
SA94:#167
intolerance,
I 3:474(abs)
SA93:#60
congestive
15:94
Exostosis,
cat scratch
dysfunction
disturbance,
Excision.
heart
14:361
failure.
13:371
Extracellular
fluid,
14:70
Exudate.
pleural,
l6:79(abs)
Eye. 16:477
disease.
15:349
SA94:#87
SA94:#47;
15:117
Ethnoiditis,
nasal septum
hematoma,
I 3:275(abs)
EPSOT
lead screening.
13:461
Epstein
pearls,
15:31 1
Epstein-Barr
virus
infection,
15:39, 63; SA93:#147;
SA94:#245
laboratory. 14:251
13:77(abs)
migraines.
test, I 3:461
enterotoxigenic,
coli,
ingestion,
SA94:#4
Erb palsy.
Ergotomines.
Erythema
annulare.
15:327
15:461;
Esophageal
atresia.
15:338
foreign
bodies.
16:35
varices,
14:436
Esophagitis.
13:174:
14:352
Esophagoscopy.
16:473
Esophagus,
foreign
body. SA93:#264
Ethanol.
13:273
14:190(abs)
13:429
capital
femoral,
15:440
14:423
in newborn,
I 6:356(abs)
Erythroprotoporphyrin
,
Epistaxis.
15:299
SA93:#1
mechanism
of action,
ophthalmic
ointment.
otitis media,
15:93
pertussis.
I 3:438(abs)
theophylline
interaction,
spasms.
SA93:#4
record
review,
13:75
SA93:#1
81 #274
I 4:489
fracture,
slipped
size.
Erythromycin,
Erythropoietin,
seizures,
15:348
I 3:334
Erythrocyte
absence
seizures,
SA93:#103
afebrile
seizures,
13:305
cognitive
and behavioral
consequences,
l5:367(abs)
SA95:#205
Environmental
hazards,
Enzyme
immunoassays.
nodosum,
14:475
cat scratch
disease.
16:248
transmission,
I 5:461
Enterovirus.
Enuresi
Eosinophilia,
I 6:433
Eosinophils.
nasal smears,
SA93:#300
Epicutaneous
testing,
14:240
Epidemiology.
I 3:283
Epididymitis,
14:180
Epidural
abscess.
14:364
hematoma,
15:213
Epiglottitis,
14: 19, 281
young
adult,
14:281
infectiosum,
I 3:236(abs);
16:474(abs)
migrans.
Lyme disease,
15:167
multiforme
cat scratch
disease.
15:348
Stevens
Johnson
syndrome.
SA95:#159
disorders,
15:497(abs)
fixation,
injuries,
use
newborns,
13:422
of goggles.
prophylaxis.
Eyelid
13:262
13:422
newborns,
swelling,
13:262
16:163
F
Face shape.
16:1 15(abs)
Factor
VIII. 16:290
IX, 16:290
Failure
to thrive
diabetes
insipidus.
15:201
evaluation,
SA95:#136
feeding
techniques.
SA95:#257
growth
deficiency.
immunodeticiency.
medical
record
15:69
494
psychosocial
13:453
14:226.
documentation.
dwarfism,
support
services.
I 3:64
therapy,
16:448
Fansidar,
14:95
FAST
(fluorescent
immunoassay).
allergy.
16:178
Fat, nutritional
requirements.
15:321
Fatigue
Addison
disease.
13:435
15:39
renal causes,
SA93:#222
renal tubular
acidosis,
13:391
zinc deficiency.
l6:352(abs)
371
Familial
short
Family.
16:448
stature.
blended,
15: 149(abs)
divorce.
16:306
factors,
drug abuse,
interviewing.
I 6:448
relations,
16:243
stress,
15:161
13:314
congestive
heart
psychosomatic
Fatty acids
essential,
16:243
Pediatrics’
in
Review
failure,
disorders,
14:361
15:448
SA93:#124
Vol.
/6
No.
12
1)ece,nber
I 995
I
:
.
.--
;
.
.
.
.
.
,
..
-C
.
‘I
in formulas,
Flucytosine,
B, 16:123
Fluid
electrolytes
clinical
16:107
in preterm
infants,
14:123
Fears, I3: 16; 15:384
Febrile
seizures,
13:298
epilepsy.
I 4: 1 90(abs);
SA94:#99;
15:301
14:395;
indications,
SA95:#36
syndrome,
SA94:#257,
Fluoroquinolones,
action,
15:440
Folic acid
deficiency,
goat
13:364;
#268
heart monitoring,
13:262
intellectual
outcome,
SA95:#249
lead exposure,
13:461
lung maturity,
evaluation,
SA95:#1
sickle
13:269
14:251
13:371
(parvovirus
1 3:236(abs);
SA94:#1
13:88
52
syndrome,
97
in newborn,
13:216;
13:88
Flail chest,
14:237
Flashbacks,
14:466
Flatfoot,
14:50(abs),
Fluconazole,
16:123
of
SA95:#1
SA93:#1
80
92
l6:188(abs);
395
13:387
16: 1 88(abs)
allergic
diseases,
Foot problems,
14:395
Football
and head trauma,
Forced
expiratory
volume,
Forefoot
adduction,
14:395
Foreign body, 14:41 1
aspiration,
l5:121(abs);
SA93:#296
battery,
SA95:#143
coin,
16:474(abs)
Fitz-Hugh-Curtis
14:265;
testing,
B 19),
Fine motor development,
Fistula,
tracheoesophageal,
milk,
anemia,
hypersensitivity,
intolerance,
SA94:#274
dysplasia,
mechanism
SA93:#69
of unknown
origin,
15:127
red blood cell transfusion,
15:1 22(abs)
disease
cell
Food
allergy,
29
toxins,
13:364
Fever
chronic
meningococcemia,
laboratory
evaluation,
neutropenia,
in
immunocompromised,
Fixation
SA93:#1
Flunisolide,
13:323
Fluoride,
15:311
supplementation,
15:175
SA95:#1
elemental,
SA93:#99;
SA94:#44
feeding, 15:321
for preterm
infants,
SA94:#233,
#265
hypoallergic,
I 6:107
milk,
16:107
soy, 15:321; 16:107
tube feedings,
composition,
counterpoint)
15:39
SA93:#118
Fifth
amphotericin
physiology,
Feeding
allergy
prevention,
problems,
13:33
failure
to thrive,
technique,
13:453
Femoral
anteversion,
Fibrous
with
aspects,
14:103
14:70
management,
in diabetic
ketoacidosis,
I 6:304(point-
SA95:#276
Ferritin,
Fetal
alcohol
used
16:178
SA95:#281
13:403
SA95:#193
supracondylar,
SA94:#1 75
toddler’s,
14:281
Fragile
X syndrome,
16:130,
168
characteristics,
SA95:#98
intellectual
outcome,
15:473;
SA95:#1
16:466;
SA94:#134
esophageal,
SA93:#264
ingestion,
SA93:#264
larynx,
16:69
nasal, SA93:#304
ocular,
13:422
tracheal,
14:19; SA93:#285
vaginal,
14:141
Foreskin
entrapment,
14:140
Formula,
16:107
amino
acids, SA93:#45
composition,
SA93:#1 24; SA94:#44
57
zinc content,
SA94:#1
19
Foscarnet,
cytomegalovirus,
I 6:43
Fracture
ankle,
13:429
basilar
skull, SA94:#88
child abuse,
14:215;
SA93:#217,
#306
diseases
of bone,
14:2 15
finger,
16:37
frontal
sinus,
14:389
in young
children,
14:281
occult,
14:281
orbit, symptoms,
SA95:#29
osteogenesis
imperfecta,
14:2 15;
53
Free erythrocyte
protoporphyrin,
13:461; 15:175, 299
Frenulum,
short, SA95:#4
Frontal
sinus fracture,
14:389
Functional
abdominal
pain, 14:3 13
Funerals,
pediatrician’s
role, 16:4 19
Fungal
infections
amphotericin,
16:123,
363(abs)
in immunocompromised,
14:371;
SA93:#34,
#92
treatment,
13:152;
Fungi,
16:123
Furazolidone,
Fussy
infants,
giardiasis,
16:123,
363(abs)
14:284
13:16
G
Gait disturbance,
Galactosemia,
characteristics,
13: 1 13
14:359;
16:390
sexual
Gastric
lavage,
SA93:#98
cholestasis,
I 5:233
chronic
liver disease,
14:436
Galeazzi
sign, 16:299
Gallstones,
14:155
Gamma
globulin
subclasses,
14:291
therapy,
14:226;
16:403
Ganciclovir,
cytomegalovirus,
16:43
Gardnerella
vaginalis,
14:141,
180
prepubertal
girls, SA94:#1 53
Pediatric.v
in
Review
Vol.
abuse,
/6
No.
12
14:411;
13:443
SA94:#126
ulcer,
16:257
Gastritis,
14:352;
SA93:#90
Gastroenteritis,
15:461
bloody,
SA93:#199
laboratory
evaluation,
14:251
transmission,
13:283
Gastroesophageal
reflux,
13: 174;
14:155;
15:24, 292(abs)
clinical
findings,
SA93:#307
diagnosis,
SA94:#1 69
Dece,nher
1995
metoclopramide,
I 3: 1 17(abs)
Gastrointestinal
foreign
bodies,
16:35
tract, preterm
infant,
SA93:#242
Gastroschisis,
13:50;
16:433
Gastrostomy
feeding,
15:81(abs)
Gay and lesbian
parents,
15:354
Gender,
adolescents,
16:243
Genetics,
13:138,
197(abs)
Genital
anatomy,
13:443
development,
hypospadias,
SA93:#152
495
I
I
examination.
I 3:272(abs)
ulcers.
14:180
warts,
inheritance.
14:180
Gentamicin,
14:1 1
Gesell
and Amatruda
Developmental
and Neurologic
Examination.
16:338
Gestational
age. 13:262
Giardia lamblia infection, I4:284:
15:461
transmission.
Giardiasis,
I 3:283
14:284:
15:461
Gilled
child,
14:4
Gilbert disease, 14:436: 15:233
Gingivitis,
15:31 1
Glasgow
Coiiia
Scale,
15:213
Glaucoma
in infants,
SA93:#66
management.
SA95:#99
port wine stains.
SA95:#99
Glomerulonephritis.
acute,
l6:278(abs)
15:102
Glucocorticoid,
16:266
Glucose
parenteral.
in low-birthweight
infants.
14:238
polymers.
in low-birthweight
infants.
14:123
tolerance
test, 15: 137
Glucose-6-phosphate
dehydrogenase
deficiency.
14:191
Group
B streptococcal
13:435
Growth
SA94:#19
thigh folds,
16:299
encephalopathy.
I 5:359
storage
disease,
16:390:
charts,
SA94:#24
Glycogen
stores,
in newborn,
13:262
Goat milk, anemia,
SA95:#180
Goiter.
14:481
Goitrous
hyperthyroidism.
15:417
Goitrous
hypothyroidism.
I 5:227
Gonadal
dysgenesis.
I 3:43
Gonadarche.
14:336(abs)
Gonorrhea
cervicitis,
cholestasis,
SA95:#158
chronic
diarrhea,
13:399(abs)
familial
short stature,
15:16 l(abs)
inflammatory
bowel
disease,
14:475
medical
record
hormone,
review,
sports.
SA93:#248
14:424
standardized
SA94:#232
curves
of body
index,
l3:396(abs)
Guided
imagery.
16:2 18
Guillain-Barr#{233} syndrome.
characteristics
SA93:#61
15:69
14:337
paranleters.
SA94:#43
spurt.
in adolescence,
Gower
sign, 13:391:
l6:437(abs)
Grade
retention,
16:325
Granuloma
gluteal
infantum.
16:142
Graves
disease,
14:481:
15:417:
15:185,
14:492
cystic
fibrosis.
l3:73(abs)
deficiency.
13:453;
15:39
development.
13:88
during
infancy,
SA94:#215
SA93:#247
Gray baby syndrome.
Grief,
stages.
16:419
Grieving.
SA93:#1
11
Griseofulvin,
13: 152
Group
A streptococcal
infection,
failure
complications.
13:216
diagnosis,
SA94:#247
genital
infections,
I 4:180
sexual
abuse,
13:443
ophthalmitis,
14:423
pharyngitis.
SA93:#1 73
treatment,
SA93:#241
hematuria.
Gluteal
Glycine
Glycogen
of,
SA94:#68;
13:413
mass
13:113
SA93:#137;
SA95:#89
Epstein-Barr
virus.
15:63
mortality.
SA94:#160
treatment,
SA93:#237;
SA95:#163
Gum cysts.
15:311
infection.
276
Gynecomastia.
13:371:
SA94:#64
H
illflIl(’!lZtl(’
Hat’flO/)hiluS
bacteremia.
l4:366(ahs):
fever of’ unknown
origin.
irieningitis.
I 3: 1 12(ahs):
Otitis
media,
14:320
rifampin
prophylaxis.
SA94:#63
15:127
14: 1 1
15:377
use.
496
torticollis,
SA95:#21
migraines.
increased
vs drug
13:248
15:94
characteristics,
evaluation,
SA95:#21
SA95:#133
intracranial
SA94:#208;
poverty.
0
pressure,
SA95:#232
hemorrhage,
15:369
psychosomatic
disorders.
stress/tension,
SA94:#82
treatment,
SA94:#57
Health
counseling.
15:485
risks,
I 5:448
disease,
congestive
I 6:396(abs)
SA93:#31
SA94:#148,
#188;
awareness
threshold,
l2(abs)
congenital
cardiogenic
Hearing
assessment,
13:1
otitis media,
14:320
loss, 15:115: 16:91, 411
conductive.
SA95:#91
#224
management,
SA95:#1 02
sensorineural,
SA95:#91
Heart
arrhythmia.
SA93:#20,
#105
paroxysmal
supraventricular
tachycardia.
14:273
prolonged
QT interval,
13:469;
15:437
block,
neonatal
systemic
lupus
erythematosus.
14:194
,
318;
0
tests,
14:43
meningitis.
16:466
football,
SA95:#281
Headache,
15:448,
16:218,
diagnostic
abs)
disorders,
impairment.
14:433
intracranial
SA95:#172
Hallucinogens.
14:466
1-laloperidol.
13:37(ahs)
movement
disorder.
15:391
Handwriting,
dyslexia,
13:231
Hansen
disease,
15:369
Hashimoto
thyroiditis.
15:227
Hay fever,
13:323
I-lead
banging. l3:16: SA95:#263
injury
deafness,
tilt,
trauma,
I 3:354(abs):
transmission.
I 3:283
vaccine. 15:433
postsplenectomy.
I 5:274(
Hair loss. SA93:#102
Hairy
leukoplakia.
15:63
Half-life.
drugs.
13:4 13
Hallucinations.
schizophrenia
infant walkers,
14:286(abs);
15:213: SA93:#145
shape.
16:1 l5(abs)
0;
SA95:#56
SA94:#1
48
15:115
Pediatrics
shock,
heart
l3:358(abs)
failure,
13:1 l8(abs)
DiGeorge
syndrome.
13:197(abs)
Down
syndrome.
l4:488(abs)
feeding.
SA93:#31
5
failure,
congestive.
13:33
murmur,
15:490
innocent,
SA93:#1 9
in Review
Vol. /6
No. /2
I)eeen,ber
/995
I
#{149}1
.
Heat
loss,
Hemorrhage.
in neonate,
stroke,
13:262;
14:424;
SA95:#103
I 6:257
Hemachromatosis,
13:55;
14:436
Hemangiomas,
13:371;
15:266
strawberry
or infantile.
characteristics,
SA95:#203
Hemarthrosis.
16:290
Helicohacter
pylon,
vitamins,
Hematemesis.
14:352
differential.
Hematochezia,
differential,
Hematocolpos.
Hematocrit
SA95:#206
SA94:#242
SA95:#63
15:495
anemia
Hemothorax,
14:237
Hemotympanum,
14:320, 389; 15:213;
SA94:#88
Henoch-Schoenlein
purpura.
13:130
nephrotic
cytomegalovirus,
SA95:#62
16:41 1
evaluation,
Hemiplegic
15:94
Hemoglobin
anemia
in infancy,
15:175
glycosylated.
diabetes,
15:137
newborn,
I 6:356(abs)
I 3:469
G-6-PD
deficiency,
hemolytic-uremic
in newborn,
14:191
syndronie,
vaccine,
Hepatitis
characteristics,
splenectomy,
tyrosinemia.
Hernia
diaphragmatic.
SA93:#228
hiatal. 14:155
334
15:192:
Review
13:203.
Vol. l6
245:
14:436
15:117
edema,
aplastic
crisis,
characteristics,
13:163
inheritance,
SA94:#8
prenatal
diagnosis.
13: 138,
treatment.
SA93:#8
245
13:203;
13:387
spherocytosis
SA94:#161
in
13:203,
carcinoma,
Hepatosplenomegaly.
in histiocytosis,
Hereditary
angioneurotic
Hemophilia.
13:183:
16:290
HIV disease,
SA95:#94
Pediatrics
13:203;
14:436
SA94:#280
in newborns,
15:433
C. transfusions,
Hepatoma,
SA93:#95;
prognosis.
1 5:246(abs)
epidemiology,
Hepatocellular
14: l52(abs)
No. /2
Decen,!,er
/995
15:2
l5:2l2(abs)
15:245(abs)
I 5:274(abs)
15:359
14:431
brain
stem,
13
nucleus
pulposis.
16:458
Herpes
simplex
encephalitis.
SA93:#272;
SA94:#249
genitalis,
neonatal
13:107,
infection,
443; 14:141
13:107;
virus, 13:107: 14:180
laboratory
diagnosis.
14:251
zoster,
13:107:
SA93:#234
Heterophile
antibodies.
15:39. 63
High-risk
behaviors,
15:485
Hip
congenital
dislocation.
SA93:#31
characteristics,
SA95:#286
evaluation,
(abs):
SA95:#286
of mannequins
I3:244
dysplasia.
in training.
13:262
16:458:
SA94:#127
in ankylosing
spondylitis.
14:1
17
Hirschsprung
disease,
13:25, 50:
15:289,
338; 16:5; SA93:#132
Hirsutism,
SA94:#1 70
Histamine
2 (H2) antagonists.
peptic
ulcers,
16:257
HistocytosisX.
13:371: 15:117:
SA93:#206
Hitting,
15:366
HLA antigens.
14: 1 I 7
Hoarseness,
16:69; SA94:#196
Hodgkin
lymphoma,
SA93:#38
sepsis,
1 3:302;
I 5:246(abs)
SA94:#219
Hemolytic
disease
of the newborn,
15:422
Hemolytic
transfusion
reactions,
15: 122(abs)
Hemolytic-uremic
syndrome.
14:218
SA95:#228
management,
233:
SA95:#266
transfusions.
of
brain, 15:241
cerebellar
tonsils,
pain.
13:245:
14:218
14:191
Hemolytic
anemia
autoimmune.
13:469;
penicillin.
13:262
l5:42(abs),
transfusions,
13:203
transmission.
I 3:283
viral, 13:203, 245
Hepatitis
A. 16:283
epidemiology,
13:203;
SA93:#144
exposure,
SA94:#253
gamma
globulin,
16:403
prophylaxis.
13:245;
SA94:#96
Hepatitis
B, 16:283
chronic
active,
SA92:#228
epidemiology.
13:203
prophylaxis
in exposed
newborn,
SA95:#45
migraine.
Hemolysins.
Hemolysis
virus,
SA93:#57
SA93:#58
syndrome,
14:30
evaluation,
SA95:#126
Herniation
use
maternal.
neonatal,
I 5:102
Hemiparesis.
vasculitis.
14:436
Epstein-Barr
virus,
15:63
fever.
15:127
human
immunodeficiency
14:371
subdural,
15:213
thigh,
blood loss,
microscopic.
nephrotic
radiologic
SA95:#41
16:290
chronic active, 13:203: 15:246
chronic
liver disease,
14:436
14:424
Hematuria,
syndrome,
Hepatitis,
inguinal,
SA93:#46
internal,
16:433
intra-abdominal,
I 6:433
strangulated,
I 6:433
SA94:#263
SA93:#75;
SA94:#201
15:175
newborn,
13:262;
16:356(abs)
normal
values
adolescent.
SA94:#1
17
preterm
vs full-term,
SA95:#170
Hematoma
epidural.
15:213:
SA93:#145,
#189
nasal septum,
l3:275(abs):
SA94:#230
Hemoptysis.
13:185
characteristics,
of infancy.
sports.
16:290
intracranial,
15:369
intraventricular,
I 5:213
middle ear, 15:2 13
retinal,
SA94:#1 89
subarachnoid,
I 5:213
Hemorrhagic
disease
in preterm.
14:123
ofthe newborn, 13:163, 262: 14:191
SA94:#61
l6:456(abs)
splenectomy,
16:456(abs)
supraclavicular
lymph
node
enlargement.
I 6:456(abs)
Home
monitors
apnea,
14:51
diabetes,
15:137
Home
Screening
Questionnaire
(HSQ).
16:338
Homosexual
parents.
15:354
Homosexuality,
14:401
Homovanillic
acid, neuroblastoma.
I 5:391
Hospice
care.
16:419
Hospitalization,
preparation.
13:1 26(abs)
Hostility.
14:380
Human
diploid
cell culture
vaccine.
rabies,
14:280
Human
herpesvirus
6. SA94:#197
Human
immunodeficiency
virus
(HIV),
16:283:
SA93:#10
497
I
,
.
2;
cocaine
use, 15:89
hemophilia,
16:290;
SA95:#94
in neonates,
15:42(abs)
infection,
13:443;
16:426
diaper
dermatitis,
16:142
fungal
infections,
16:123,
363(abs)
management
by pediatrician,
14:371
sexual
abuse,
I 3:443
spinal cord lesions,
14:364
testing,
transfusions,
I 5:246(abs)
Human
milk
composition,
SA93:#1 82
immunoglobulins,
SA94:#1 84;
SA95:#246
in preterm
infants,
14:123
maternal
drugs,
13:413
penicillin,
16:83
Human
papillomavirus.
14: 180; 16:37
Hyaline
membrane
disease
etiology,
SA95:#1 51
evaluation
of amniotic
fluid,
SA95:#1
29
Hydrocarbons,
14:41 1
Hydrocele,
15:286
Hydrocephalus
diagnosis,
SA93:#41
meningitis,
14:11
myelomeningocele,
I 3:293(abs);
15:480
shunt malfunction,
13:295
Hydrogen
breath
test, I 3:437(abs)
Hydrometrocolpos.
13: 129(abs)
Hydronephrosis,
13:25;
15:480
complications,
SA94:#299
Hydrops
fetalis,
I 3:236(abs);
SA92:#274
Hydroxa.zine,
urticaria,
13:387
Hymen
imperforate,
injuries,
15:495
13:443
Hymenoptera
sting,
14:246(abs);
16:355(abs)
Hyperactivity,
14:455;
16:75
Hyperammonemia,
15:359
in neonate,
SA95:#219,
#254
Hyperbilirubinemia,
15:422;
16:323
alpha-I
-antitrypsin
disease,
biliary
cysts,
16:155
breastfeeding,
15:422
cerebral
palsy,
16:4 1 1
cholestasis,
15:233
chronic
liver disease,
14:436
evaluation,
SA94:#283
hemolytic
anemia,
13:469
hemolytic
disease,
15:422;
hepatitis,
13:203,
245
hereditary
spherocytosis,
I 5:245(abs)
neonatal,
13:362;
15:253
(commentary),
422
498
14:493
1.
G-6-PD
deficiency,
physiologic,
I 4: 191
pyloric
vs preterm
infants,
unconjugated,
SA93:#198
Hypercalcemia,
SA94:#301
Hypercalciuria,
15:80(abs),
102
laboratory
evaluation,
SA95:#287
Hypercapnia,
manifestations,
SA93:#5
Hypercholesterolemia
nephrotic
syndrome,
14:30
risk factors,
SA93:#205
Hyperglycemia,
I 5: l 37
Hyperkalemia
acute renal failure, 16:101, 137
cardiac
effects,
SA93:#20
treatment,
SA93:#1 96
Hypermobility
syndrome,
characteristics,
16:29
14:103;
Hypoglycemia
associated
15:201;
complications,
SA94:#21
1
diabetes
insipidus,
15:201
Hypersensitivity
penicillin,
14:152(abs);
16:83
treatment,
I 3:387
Hypersplenism,
I 3:55
Hypertension,
14:169
drugs for treatment,
16:229
evaluation,
SA94:#1 23
SA94:#1
purpura,
30
cystic
fibrosis,
I 3:183
Hyporetinemia.
16:358(abs)
Hypospadias,
I 4:494(abs)
Hypothermia,
drowning,
14:148
Hypothyroidism,
15:227
congenital,
15:359
causes,
SA95:#125
characteristics,
SA95:#52
laboratory
evaluation,
SA93:#209;
goitrous,
transient
Hypotonia,
botulism,
cerebral
9
nephrotic
syndrome,
14:30
Hypocalcemia
characteristics,
SA93:#91
DiGeorge
syndrome,
13:1 97(abs)
low-birthweight
infants,
14:123
Hypochloremia
Hypoxemia,
SA95:#1
15:227
congenital,
l6:437(abs)
14:117
palsy,
16:41
degenerative
15:227
1
disorders,
cor
25
16:426
pulmonale,
SA95:#191
Hypoxia,
neonatal
seizures,
16:248
Hypoxic-ischemic
encephalopathy,
newborn,
SA93:#1 04, #303
Hysterical
personality,
16:29
15:192
Pediatrics
SA94:#149
Hypokalemia,
14:70,
103
characteristics,
SA94:#251
diabetes,
15:137
diuretic
therapy,
SA95:#174
treatment,
SA93:#96
Hyponatremia,
14:70,
103
anasarca,
SA93:#127
cystic
fibrosis,
SA94:#137
manifestations,
SA95:#235
neurologic
findings,
SA95:#1 22
Rocky
Mountain
spotted
fever,
13:269
total body sodium,
SA93:#127,
#190
treatment,
SA94:#225
Hypoplasia,
pulmonary,
l4:43l(abs)
Hypoproteinemia,
SA94:#302
13:130
in children,
SA93:#72
intracranial,
SA95:#166
neurofibromatosis,
14:433
pulmonary,
14:43 l(abs)
renal, 16:101, 137
steroid
use, SA93:#40
symptoms,
SA94:#1 20
treatment,
SA93:#202;
SA94:#1
79
Hypertensive
encephalopathy.
1 6:278(abs)
Hyperthyroidism,
15:417
laboratory
evaluation,
SA93:#61
treatment,
SA94:#223
Hypertonia,
metabolic
disorders,
15:359
Hypervitaminosis,
I 3:185
Hyphema.
13:422
Hypnotherapy,
I 6:218
Hypoalbuminemia
drug-protein
binding,
SA95:#231
effect on serum
theophylline
levels,
fibrosis,
conditions,
diabetes,
15:137
drugs for treatment,
16:229
ethanol
ingestion,
15:1 17
evaluation,
SA93:#50
in preterm,
14:123,
238(abs)
Iow-birthweight
infants,
I 4:238(abs)
metabolic
disease
of newborn,
15:359
neonatal,
13:262
seizures,
16:248
very-low-birthweight
infants,
16:3 16
Hypohidrotic
ectodermal
dysplasia,
SA93:#268
Henoch-Schoenlein
nephritis,
SA93:#241
SA95:#77
Hypernatremia,
in cystic
SA93:#226;
Hypocomplementemia,
SA93:#77
SA93:#21
stenosis,
SA94:#85
Hypochondriasis,
I 5:422
in term
I
,
i,i
Review
Vol.
16
No.
12
December
in
1995
I
1
.t4
I
Ichthyosis
vulgaris,
15:220
management,
SA93:#1 65;
SA95:#1
37
Identity,
16:158
Idiopathic
thrombocytopenic
13:163; SA93:#27
IgA nephropathy,
15:102
Illegal
drugs,
l5:372(abs)
Imaging,
sinusitis,
14:345
Immediate
hypersensitivity,
Immune
dysfunction,
14:226
Immune
globulin,
13:l43(abs)
anaphylaxis,
SA93:#252
side effects,
SA93:#252
varicella-zoster,
indications,
SA93:#1
purpura,
13:387
01
Immune
thrombocytopenic
purpura,
aspirin,
SA94:#272
Immunity,
specific,
SA93:#214
Immunizations,
I 3:98
diphtheria,
SA93:#201
egg allergy,
SA95:#18
human
immunodeficiency
virus,
14:371
in adolescence,
SA93:#52
in immunodeficient,
SA94:#1 66
in preterm
infant,
SA95:#255
influenza,
SA93:#68
pertussis,
SA93:#201
#221
pneumococcal,
SA93:#276
school
entry,
13:98
tetanus,
SA93:#1 25
vaccine
administration,
15:433
Immunocompromised
patients
nontuberculous
mycobacteria,
16:223
Pneumocystis,
SA94:#1 35
varicella
exposure,
SA93:#1 00
Immunodeflciency,
14:226
complications,
SA93:#273
diseases,
16:403
evaluation,
SA93:#200;
SA95:#200
IgG subclasses,
14:291
immunizations,
13:98; SA94:#166
screening
tests, SA93:#200
treatment,
SA93:#34
Immunofluorescent
test, Chiamydia,
14: 180
Immunoglobulin
content
of human
milk, SA94:#184;
SA95:#246
disorders,
14:226
E antibody
tests,
16:178
E, penicillin
reaction,
l4:152(abs)
levels in immunodeficiency,
,
SA93:#200
Imperforate
anus,
15:319(abs),
338
hymen,
15:495
Inappropriate
secretion
of antidiuretic
hormone,
14:1 1; SA93:#238
Inattention,
14:455
Inborn
errors of metabolism,
16:426
characteristics,
SA95:#21
9
homocystinuria,
SA95:#39
hypoglycemia,
SA95:#279
seizures,
I 6:248
vitamin
dependence,
SA95:#39
Incontinence,
stool,
16:5
Index of suspicion,
13:33,
1 13, 157,
269,295,391,469;
14:117, 155,
191, 215, 281, 361, 433; 15:39,
1 17, 201, 289, 369, 391, 495;
16:37,
1 17, 155, 223, 349, 433
Infancy,
behavioral
problems,
13:16
Infant
formula,
16:107
composition,
SA93:#1 24;
SA94:#44
newborn
and premature,
care,
13:262
preterm-see
Premature
infant
walkers,
I 4:286(abs)
Infantile
obstructive
cholangiopathy,
15:233
Infantile
spasms,
natural
history,
SA93:#4,
Vol. 16
No. 12
SA94:#29
SA95:#13
chlamydial,
13:216
drug abuse,
SA95:#79
fungal, 13:152
group
B streptococcal,
in immunocompromised,
SA93:#34,
#92;
SA94:#135,
13:143(abs)
SA93:#100;
#274;
SA95:#145
in immunodeficient,
14:226
streptococcal,
SA93:#1 67
travel history,
SA95:#244
Infectious
diseases,
transmission,
13:283
Infectious
mononucleosis,
15:39,
SA93:#147;
SA94:#245
Infertility,
pelvic
inflammatory
disease,
13:216
Inflammatory
bowel
disease,
SA94:#59
growth
failure,
SA95:#66
Influenza
amatadine
therapy,
15:377;
SA93:#1
33;
antigen
detection,
treatment,
SA93:#1
vaccine,
SA93:#68
December
1995
63;
14:475;
SA94:#21
SA94:#21
33; SA94:#21
SA95:#1
54
knee and ankle,
13:429
neck,
16:28(abs)
prevention,
13:276(abs)
spinal cord, SA93:#116
sport, 16:184
Insect
bites,
16:355(abs)
stings,
l4:246(abs)
venoms,
Insomnia,
I 3:387
cocaine
Inspissated
Infection
asplenia,
SA95:#1
10
beta-lactamase
production,
subclasses,
14:291;
SA93:#232
therapy,
16:403
Immunotherapy,
allergic
disorders,
16: 178
Pediatrics in Review
#106;
Influenza
A, SA93:#133
Informed
consent,
for immunization,
15:433
Ingestion
amitriptyline,
SA95:#34
battery,
management,
SA95:#143
phenobarbitol,
SA93:#1 12
Inguinal
hernia,
15:286
Inhalers,
use, SA93:#1 1 3, #296
Inheritance
pattern,
SA94:#1 29
Inherited
disorders
of central
nervous
system,
13:157
Inhibitors,
hemophilia,
16:290
Injury
athletic,
14:424;
SA93:#65;
bile
abuse,
syndrome,
14:361
15:233
Insulin,
15:137;
SA93:#227
-dependent
diabetes,
15:137
Intelligence
quotient
(IQ), 13:231;
14:4; 16:338
Intelligence
tests,
13:231;
14:4;
16:338,
342; SA94:#221
International
pediatrics,
14:95
Interview,
drug abuse,
13:314
Intestinal
function,
effects
of
chemotherapy,
SA94:#234
Intestinal
obstruction,
16:433
Henoch-Schoenlein
purpura,
13:130
Hirschsprung
disease,
15:289
in newborn,
15:338;
16:5
Meckel
diverticulum,
15:289
In-toeing,
SA93:#1
18
Intoxication,
14:41 1
Intracellular
fluid, 14:70
Intracranial
bleeding,
headache,
SA94:#304
hemorrhage.
15:369
hypernatremic
dehydration,
I5:201
herniation,
I 5:241
pressure,
increased,
15:204,
241
diagnosis,
SA93:#41,
#63
headache,
SA94:#208;
SA95:#232
Intractable
Intraluminal
Intrauterine
13:334;
diarrhea,
feeding,
growth
SA93:#104
l4:3l2(abs)
l4:3l2(abs)
retardation,
499
I
.5
1
5#{149}5
Intravenous
access.
gamma
S
Ipecac.
14:411
IQ scores, 13:231: 14:4: 16:338:
14:237
globulin.
16:403
immunoglobulin.
SA94:#221
human
virus. 14:37
immunodeficiency
Intrinsic
renal failure.
Intuhation
tube size in children.
use of mannequins
13:244
Intussusception.
.‘
1
I 5:253(abs)
SA95:#278
in training,
13:50,
391;
14:302
Iridocyclitis.
in ankylosing
spondylitis.
14:117
lritis,
16:477
Iron
deficiency
anemia.
14:123:
lead poisoning,
13:461
medical
record
review.
15:175
15:299
I
S
fortification,
I 3:36(abs)
overdose,
13:273:
14:411:
15:151
stores,
in neonates.
SA94:#222
Irritability, cocaine abuse, 14:361
Irritable
bowel
syndrome.
l3:397(abs);
14:313:
15:389
Isoniazid,
tuberculosis,
13:343
Isotretinoin
(Accutane),
15:47
Isovaleric
acidemia,
15:359
Itraconazole,
16: 123
J
Jaundice-see
Hyperbiliruhinemia
Jimson
weed,
14:466
Joint pain. hypermobility
syndrome.
SA95:#77
Juvenile
rheumatoid
arthritis.
SA93:#233
cardiac
uveitis.
complications.
16:477
SA94:#1
13
K
Kallman
syndrome.
13:43
Kartagener
syndrome.
SA94:#33
Kasahach-Merritt
syndrome.
15:266
Kaufman-ABC
test. 16:325
Kawasaki
disease,
16:443:
SA93:#1 85
coronary
aneurysms.
SA95:#252
gamma
globulin.
16:403
thrombocytosis.
SA95:#252
treatment.
SA95:#252
Kernicterus,
14:191:
15:422
Ketoacidosis,
15: 137
diabetic,
fluid management.
16:304(point-counterpoint)
Ketoconazole.
fungal
infections,
13:152:
16:123
Kidney
disease.
13:130
enlargement.
13:25
stones,
15:80,
102, 495
toxicity.
amphotericin,
I 6:363(abs)
Klinefelter
syndrome.
13:435
features.
SA94:#1 87
intelligence,
speech
and
SA95:#236
language
deficits,
SA95:#236
Klumpke
paralysis.
13:77(abs)
Knee
injuries. 13:429
pain.
15:494(abs)
bone tumor,
13:469
Kwashiorkor,
14:95
Kyphosis.
management.
SA95:#229
L
Labial
adhesions,
lS:87(abs):
Laryngitis.
Labial
frenum,
15:311
Laboratory
data, recording.
Lacerations,
13:257.
422:
I 5:299
16:466:
SA93:#36
Lactase
deficiency.
l3:437(abs):
16: 188(abs)
Lactose
intolerance.
I 3:437(abs):
SA94:#97
irritable
bowel
syndrome.
I 3:397(abs)
recurrent
abdominal
pain.
14:313
Lange-Jervell-Neilsen
syndrome.
cell
histiocytosis.
15:1 17;
SA93:#206
Language
delay. 13:231: 15:473
causes
of, SA95:#169
school
problems.
SA95:#224
development.
14:4: 16:91
disorder.
14:455
hearing
disorders.
14:43
preschool
milestones.
l5:4l2(abs)
skills,
I4:15l(abs):
16:325
Sot)
SA95:#8
vs tracheomalacia,
SA95:#8
Laryngoscopy,
SA93:#246
Latex particle
agglutination.
14: 1 1:
16:62
test in meningitis,
SA93:#85;
SA95:#1
00
Laurence-Moon-Biedle
syndrome.
14:337
Laxatives.
14:447:
16:5
Lead poisoning, 13:461; 16:433
anemia.
medical
record
review,
13:461
14:43
Langerhans
16:69
Laryngomalacia
characteristics.
SA94:#277
management.
13:461:
SA94:#39
nondietary
sources.
SA95:#253
Learning
disabilities.
I 4: 157(abs).
2 14(abs):
15:473:
16:325
evaluation,
l4:2l3(abs):
SA93:#308;
SA95:#208
management,
SA94:#1
78;
14:2 13(abs):
SA93:#262
outcome,
l4:2l4(abs)
Pediatrics
disorders, 14:455; 15:497; 16:75
effect of medications,
SA93:#301
problems.
13:312
Leg pain. 16:458
Legg-Calv#{233}-Perthes
disease,
16:458
characteristics,
SA95:#1 20
Length.
growth,
13:88
Lens,
13:422
Leprosy.
15:369
Leptospirosis.
15:276
Lesbian
and gay parents.
15:354
Lethargy.
14:117
in intestinal
obstruction,
16:433
Leukemia,
16:226
acute lymphoblastic.
16:155
associated
conditions,
I 6:155
blastemia,
16:155
bone pain. 16:155
Leukokoria,
13:7
Leukopenia.
16:226
Lice.
l6:336(abs)
Lichenification,
15:327
Lid lacerations.
I 3:422
Life style.
16:243
Limb-girdle
muscular
dystrophy,
13:391
in Review
Vol.
16
No.
/2
December
1995
Fl
‘.5
Limb length
inequality,
16:458
Limp,
16:458
differential
diagnosis,
SA95:#120
Legg-Calv#{233}-Perthes
disease,
SA95:#1
20
Lindane,
15:110;
l6:336(abs)
Lipid,
content
in formula,
16:107;
SA93:#1
24
Lipomas,
13:371
Lisch nodules,
in neurofibromatosis,
14:433
Listeria
monocytogenes,
1 3:277(abs)
Listeriosis,
13:277(abs);
14:262
Lithium,
13:364
Liver
abscess,
amebic,
treatment,
Low birthweight
parenteral
glucose,
l4:238(abs)
prevention,
13:64
vs preterm,
increased
14:436,
SA93:#1
493(abs);
40
transplantation,
Long QT interval,
Lorazepam,
status
intracranial
pressure,
15:241
opening
pressure,
SA95:#23
use of mannequins
in training,
13:244
Lung
infections,
15:192
overaeration,
15:1 62(abs)
Lupus,
14:194
complications
of therapy,
SA95:#42
laboratory
evaluation,
SA95:#1
Lying
and stealing,
SA94:#107
SA95:#24
disease,
SA95:#64
Low self-esteem,
15:485
Lower
airway
obstruction,
15: l62(abs)
LSD,
14:466
Lumbar
puncture
15:233
13:469;
15:437
epilepticus,
16:386
48
Lyme disease,
15:167
arthritis,
SA94:#98
causative
agent,
SA95:#57
diagnosis,
I 5:2 19(abs)
treatment,
15:167
Lymph
nodes,
13:371
Lymphadenitis,
due to
nontuberculous
mycobacteria,
14:263(abs);
16:223
Lymphadenopathy,
13:371
atypical
mycobacterial,
l4:263(abs);
16:223
cat scratch
disease,
15:348
cervical,
13:113;
14:263(abs);
15:276;
SA93:#37
evaluation,
SA95:#21
2
histiocytosis,
15:117
Lymphoid
interstitial
pneumonitis,
14:371;
15:63
Lymphoma,
Hodgkin,
SA94:#1
80
Lymphoproliferative
syndromes,
15:63
M
Macrocephaly,
SA93:#1 8
Macrocytosis,
I 5:299
Magnetic
resonance
imaging,
osteomyelitis,
16:380
Mainstreaming,
16:325
Marijuana
abuse,
13:314
effects,
SA93:#1
substance
abuse
Malabsorption
Mass,
left upper quadrant,
13:25
Mastoiditis,
14:320;
SA93:#284
diagnosis,
SA95:#1
57
Masturbation,
I 4:401
Maternal
chronic
illness,
impact
on fetus,
I 6:354(abs)
drug use, impact
on fetus,
I 6:354(abs)
drugs,
13:262
Mauriac
syndrome,
diabetes,
15:137
McCune-Albright
syndrome,
15:4 17
Mean corpuscular
volume,
15:299
Measles,
16:283,
358(abs)
complications,
SA93:#240
immunization,
SA94:#83
human
immunodeficiency
virus,
14:371
transmission,
16:283
vitamin
A supplements,
16:358(abs)
Measles,
mumps,
rubella
vaccine,
14:245(abs)
Mebendazole,
pinworms,
l6:247(abs)
Meckel
diverticulum,
13:50;
14:302;
15:289;
SA94:#106
Meconium
ileus,
15:192,
338; SA93:#175
SA94:#297
allergic,
16:178
carbohydrate,
I 3:437(abs)
cystic fibrosis,
15:192
inflammatory
bowel
disease,
14:475
vitamins,
13:185
Maladjustment,
14:447
Malaria,
14:95
Malathion,
lice, l6:336(abs)
Malignancy,
13:371
nutritional
problems,
SA95:#22
Malingering,
16:29
Mallet
finger,
16:37
Malnutrition,
SA94:#1 95
assessment,
14:492
failure
to thrive,
13:453
tropical
pediatrics,
14:95
Malocclusion,
15:31 1
Malrotation
of intestine,
14:302;
15:338
Mania,
14:380
Mannequins,
13:244
Mantoux
test, 13:343
Maple
syrup urine disease,
15:359
Marasmus,
14:95
Marfan
syndrome
cardiac
complications,
SA94:#147
characteristics,
SA93:#21
6;
nasopharyngeal
1 3:237(abs)
plug, 16:5
SA94:#147
pneumothorax,
Pediatrics
in Review
l3:398(abs)
Vol.
/6
28
screening,
No.
12
December
/995
suction,
syndrome,
15:3 19(abs)
stained
amniotic
fluid, 13:262;
15:255; SA95:#96
Medial
femoral
torsion,
SA93:#1
18
Mediation,
divorce,
16:306
Medical
record
review
anemia
and other
‘laboratoryintensive”
disorders,
15:299
asthma,
I 3:203
artentional
disorder,
16:75
chronic
abdominal
pain,
14:67
failure
to thrive,
15:69
head injury,
14:299
migraine,
16:3 18
otitis media,
13:355
seizures,
13:75
Medical
records,
in Program
for
Renewal
of Certification
in
Pediatrics,
13:13 1
Medication
administration
to children,
13:195
palatability,
I 3:195
side effects, 16:333
Medium-chain
triglycerides,
14:123;
16: 107
Medullary
thyroid
carcinoma,
14:481
Megacolon,
aganglionic,
15:289
Megaloblastic
anemia,
goat milk,
‘
SA95:#1
80
Melanoma,
13:371
characteristics
of, SA95:#1
congenital,
16:365
Membranoproliferati
ye
glomerulonephritis,
14:30
Membranous
glomerulonephritis,
14:30
16
501
I
S#{149}
Methanol.
13:273:
14:411
Methemoglobin.
14:41 1
Methicillin.
16:83
Methimazole,
I 5:417
Methylmalonic
acidemia.
15:359
Methylphenidate.
15:5: 16:75:
Menarche.
15:39:
Meniere
disease.
15:115
Meningitis
aseptic.
14:155
bacterial.
14: 1 1
compi ications
deafness.
SA95:#56
subdural
effusion,
causes, 14:155
complications.
fungal.
SA94:#1
findings.
90
laboratory
evaluation.
14:251:
SA93:#85
partially
treated
diagnosis.
SA95:#100
management.
SA94:#21
prophylaxis,
I 3:370(ahs)
rapid diagnosis.
SA95:#100
transmission.
16:283
Meningococcal
infection
prophylaxis.
l3:354(ahs):
4
15:377:
SA94:#89
SA94:#270
retardation,
16:91
14:455:
age ofdiagnosis.
15:473:
SA95:#17
definition.
SA95:#59
evaluation.
SA95:#18
Fragile
X syndrome.
gross motor
development.
SA95:#153
in infancy.
quotient.
SA93:#286,
#313
mild. independent
niucopolysaccharidosi
living.
SA95:#5
s. SA95:#72
14:466
carbohydrate.
16:390
fat. 16:390
inborn
errors.
16:390:
#195;
SA93:#50,
SA94:#66
16:390
Metachroiiiatic
leukodystrophy.
16:426
Metatarsus
adductus.
varus,
14:395
14:395
Methamphetamine.
13:330:
14: 101 (point-counterpoint)
502
disease,
Movement
drinking.
13:323
15:311
disorders,
drug-induced,
15:391:
Mucoceles,
13:371
Mucocolpos.
15:495
Mucopolysaccharidosis.
mental
retardation.
SA95:#72
Multiple
endocrine
neoplasia
(MEN),
14:48 1
Multiple
mucosal
neuromas,
14:481
Mumps.
16:349
associated
findings.
SA94:#294
complications.
SA93:#210
pancreatitis.
SA93:#21
0
transmission.
16:283
Munchausen
syndrome
by proxy.
I 5:320(abs)
Muscular
dystrophy.
13:391;
blindness.
24 months,
SA95:#81
3 years. SA94:#202;
SA95:#169
loss of. degenerative
disease.
SA95:#144
I 6:437(ahs)
complications.
SA95:#12
Duchenne,
16:437(abs):
SA93:#174
facioscapulohumeral.
I 6:437(abs)
niotor
Metabolic
acidosis.
SA94:#54
Metabolic
disorders
central
nervous
system.
13:157
coma.
SA94:#66
evaluation,
SA93:#50,
#195
in newborn,
15:359
prenatal
diagnosis.
SA94:#15
Metaboli
sin
accident,
Mouth
breathing,
4 years. SA94:#276
preschool
vehicle
SA95:#97
SA95:#31
language
SA93:#286
intelligence
#171,
13:88
Motor
giardiasis.
14:284
fungal
infections,
13:152
SA93:#1
75
I 5:299
I 6:352(abs)
I 5:288(abs)
balance
disturbance,
15:369
cleft palate.
l6:424(abs)
effusion.
13:355:
15:93
Migraine,
15:94:
16:318
characteristics,
SA95:#21
0
medical
record
review.
16:318
Milestones
cognitive.
7 months,
SA95:#227
developmental
3 years. SA95:#152
infant
SA94:#51
protein.
Metronidazole,
Miconazole,
Microcolon,
Microcytosis.
Micronutrients.
Micropenis.
Middle
ear
disease
SA93:#247;
Mescaline.
side effects,
SA94:#141
Methylthiotetrazole,
I 5:54
Methylxanthine.
half-life.
SA94:#32
Metoclopramide
gastroesophageal
reflux,
I3: 198(abs)
movement
disorder,
15:391
toxicity. 13:1 17(abs)
transmission.
13:283:
16:283
vaccine,
SA94:#1 50
Meningococcemia.
chronic.
13:269
Menometrorrhagia.
causes.
Mental
Moles,
malignant.
16:365
Molluscum
contagiosum.
management.
SA93:#22
Mongolian
spots.
14:215
Monitoring.
sudden
infant death
syndrome,
14:83
Monoclonal
antibodies,
16:290
Mononucleosis,
15:39. 63. 127
A’loraxella
(‘atarrhalis,
otitis media,
14:320
Morphea.
I 6:49(abs)
Mothballs,
poisoning,
14:41 1
Mother-infant interaction, 13:453
Motor
development.
assessment,
SA93:#262
SA95:#265
13:1 I2(ahs)
laboratory
I
.
,
limb-girdle.
2 months,
SA95:#1
19
18 months,
SA94:#1
18
3 years.
SA94:#46
4 years,
SA95:#1
5 years.
SA94:#1 39
socio-emotional
16 weeks,
SA94:#183
3 years.
SA95:#152
visual,
infant,
SA94:#76
Milk
cow, l3:36(abs): 16:107
sleep
I6:437(abs)
disorders,
13:11 6(abs):
SA93:#174
Mushrooms,
Myasthenia
14:361
Mycobacteria
atypical.
14:411
gravis.
13:38(abs):
nontuberculous.
14:263(abs):
SA93:#1 55
Mycobacterial
I 3:37 1:
15:276:
16:223:
lymphadenitis.
14:263(abs):
15:276:
I 3:37 1:
16:223
leprae.
I 5:369
Mycoplasma.
14:251
Myelomeningocele.
I 3:293(abs):
I 5:480
complications.
SA94:#90,
#287
disordered
sleep,
13:1 16(abs)
Myelopathy.
14:364
Myocarditis,
15:87
manifestations,
SA95:#71
human.
16:107
vitamin D. 13:185
Mvcohac’teriu,n
intolerance.
I 3:437(abs)
nutrition,
15:321
Minnesota
Child
Development
Inventory,
16:338
Minerals.
14:123
in formulas,
16:107
Mitral
insufficiency.
I 4:272(abs)
Pediatrics
iii
Reviesv
Vol.
/6
No.
/2
l)eeember
/995
S
#{149}
Myoclonic
Myoclonus.
seizures,
16:248
16:248
Myopathy.
Myopia.
16:266
I 5:497(abs)
Myringotomy.
Myxoma.
13:355:
atrial.
14:320
16:155
N
N-acetylcysteine.
14:41
systemic
lupus erythematosus.
14: 194
withdrawal
syndrome.
14:466:
15:89
Neoplasms.
15:127
of the bone,
16:458
1
Nafcillin
side effects.
SA94:#48
Naloxone,
13:273
Narcotic
overdose,
13:273
Nasal
discharge.
choanal
atresia,
I 6:475(abs)
eosinophils.
13:323;
SA93:#300
obstruction,
choanal
atresia,
I 6:475(abs)
polyps,
15:192
septum.
hematoma.
I 3:275(abs)
Nephritis.
smears,
for eosinophils,
13:323;
SA93:#300
stuffiness in infants,
SA93:#295
Nasolacrimal
duct obstruction.
I 5:88(abs)
Nasopharyngeal
14:226
Neurodiagnostic
injury.
16:28(abs)
mass, differential,
SA95:#69
Necrotizing
enterocolitis,
15:24, 338
radiologic
findings,
SA95:#121
Needle,
and bone marrow
aspiration.
15: 157
to thrive,
abuse,
Neisseria
meningitiths.
l3:370(abs):
14:11
management,
59
bacteremia.
therapy.
SA93:#23
behavioral
assessment
scale,
drug withdrawal,
13:314
eye prophylaxis.
13:88
idiopathic.
Nevi,
SA94:#293
16:209
13:435
seizures,
sepsis.
Pediatrics
16:248
13:435
iii
Reviess
Vol.
16
SA93:#1
64
13:371
malignant.
16:365
Newborn
afebrile
seizures,
13:305
anemia,
16:356(abs)
bleeding
disorders,
13:163
cardiogenic
shock,
l3:358(abs)
chronic
hepatitis,
I 3:203,
245
cyanosis.
1 5: 1 5 1 (abs)
14:423
Graves
disease,
15:417
meningitis.
14:1 1; SA93:#23;
mortality,
pneumonia.
#114,
evaluation.
SA93:#32
Lisch nodules,
SA95:#7
neurofibromas,
SA95:#7
Neurogenic
bladder,
15:480
Neurologic
development,
I 3:88
Neuropathy.
SA93:#26
in leprosy.
15:369
Neutropenia,
SA94:#248
differential
count,
SA95:#220
immunodeficiency,
14:226
13:453:
15:39
15:394
prevention,
syndrome.
SA94:#1
SA93:#32,
#283
Neonatal
abstinence
13:248
SA95:#92
characteristics,
Neglect
failure
physical
tests,
Neurofibroma,
13:371
Neurofibromatosis,
14:433
caf#{233}-au-lait spots in. SA93:#283;
Neck
No.
/2
December
1995
I3:237(ahs)
screening.
15:359
sepsis. 14:262
Niacin.
Nephrogenic
diabetes
insipidus.
15:201
Nephrolithiasis,
lS:80(abs),
102
Nephrotic
syndrome.
14:30, 70, 226
characteristics,
SA95:#260
laboratory
evaluation,
SA95:#260
minimal
change.
SA95:#260
peritonitis,
14:226;
SA94:#186
Nephrotoxicity,
amphotericin
B,
I 6:363(abs)
Neural
crest tumors,
15:391
Neural
tube defects,
13:334
Neuritis,
Epstein-Barr
virus.
15:63
Neuroblastoma,
15:391
abdominal
masses,
13:25
hypertension,
14:169
Neurocutaneous
melanosis,
16:365
Neurodegenerative
disease,
I 6:426
sinus fracture, 14:389
carcinoma,
15:63
suction.
I 3:237(abs)
Natural
killer-cell
deficiency.
Near-miss
apnea,
14:83
SIDS.
14:51
I 6:278(abs)
heart murmurs,
15:490
infant development.
13:88
nasopharyngeal
suction.
overdose,
14:433
Nicotine.
dependence.
14:275
Night
terrors,
SA94:#216
waking.
13:16: SA94:#30
Nightmares.
SA94:#216
Nighttime
sleeping.
SA94:#278
Nitrofurantoin,
15:377:
16:22
Nocturnal
enuresis
primary.
SA94:#87
secondary.
SA94:#47
Nodule,
14:481
Non-Hodgkin
lymphoma.
I 5:63
Nontuberculous
adenitis.
13:371:
l4:263(abs):
15:276
mycobacteria.
15:276:
I3:37 1: I4:263(abs);
16:223:
SA93:#155
Norepinephrine.
Norplant.
15:32
Norwalk
agent.
15:461
Nose
in infants, SA93:#295
breathing.
14:489
Nosocomial
spread
of infections.
13:283
Nuclear
war, fears about,
SA93:#271
Nucleotides,
in formulas,
I 6: 107
Nummular
eczema.
15:327
Nurse home-visiting.
13:64
Nursing
bottle caries,
15:31 1
Nutrients,
absorption
during
infancy.
SA95:#267
Nutrition,
15:321
behavior,
SA94:#78
evaluation.
SA94:#71
low-birthweight
infants,
I 4: 123
malignancy,
SA95:#22
parenteral.
15:78; SA94:#273
complications.
SA94:#273
indications,
SA95:#225
low-hirthweight
infants,
14:123
sports.
14:424
total. inflammatory
bowel
disease.
14:475
Nutritional
status,
assessment,
14:492
Nystagmus.
I 5:497(abs)
503
.
S
.5
.
0
Obesity,
15:321
assessment
and treatment,
14:337
standardized
curves
of body mass
index,
I 3:396(abs)
television,
13:144
uncommon
causes,
14:337;
SA93:#1
69
Obstruction
airway,
SA93:#82,
#183
intestinal,
15:338;
16:433
in neonate,
SA95:#37
nasal, choanal
atresia,
16:475(abs)
urinary,
evaluation,
SA95:#274
uteropelvic,
16:223
Obstructive
lung disease,
13:473(abs)
sleep apnea,
I 4:5 1 ; I 6:17
Occult
bacteremia,
14:366(abs)
prevalence.
SA93:#1 88, #254
treatment,
SA94:#63
Occult
blood,
in stool, SA94:#31
Ocular
weakness,
myasthenia
gravis,
14:361
Office emergencies,
I 6:466
Oliguria,
I 6:278(abs)
Omphalitis.
16:363
Omphalocele,
13:50;
16:433
Opening
pressure,
lumbar
puncture,
SA95:#23
Ophthalmia
neonatorum,
15:377
Ophthalmoplegia,
I 6:163
Ophthalmoplegic
migraine,
15:94
Opiates
overdose,
SA94:#1 03
side effects,
SA94:#250
Opportunistic
infections,
drug abuse,
SA95:#79
Oppositional
behavior,
16:448
Opsomyoclonus,
15:391
Optic
atrophy,
SA94:#92
glioma,
in neurofibromatosis,
14:433
Oral contraceptives
dysfunctional
uterine
bleeding,
13:83
risks, SA93:#293
Oral rehydration,
15:461
solutions,
composition,
SA93:#291;
SA94:#1 71
tropical
pediatrics,
14:95
Oral ulcers,
14:475
Orchitis,
SA93:#67
Organophosphates,
13:273; 14:41 1;
SA92:#1
cholesteatoma,
SA93:#21
1
chronic,
15:115
microbiology,
SA95:#25
prophylaxis,
15:377;
SA94:#70
complications,
SA93:#284
eustachian
dysfunction,
language
delay,
SA95:#224
medical
record
review,
I 3:355
recurrent,
13:23
relapsing,
15:93
tympanocentesis,
SA94:#258
Otitis with effusion,
14:43
treatment,
I 3: 199(abs)
Otorrhea
bloody,
etiology,
SA93:#109
ventilation
tubes, SA95:#146,
#245
Otosclerosis,
15:115
Otoscopy,
14:320
Ototoxicity,
aminoglycosides,
74
Orthostatic
proteinuria,
14:30
Ortoloni
test, 16:299
Osgood-Schlatter
disease,
I 3:429
Osmolality,
diabetes
insipidus,
15:201
Osmolargap,
13:273;
14:411
Osmolarity,
14:70
Osteochondritis
dissecans,
13:429
Osteogenesis
imperfecta,
14:215;
15:394
characteristics,
SA95:#193
Osteogenic
sarcoma,
I 3:469
Osteomyelitis,
15:201 ; 16:380,
458
characteristics,
SA94:#1
01
evaluation,
SA95:#259
fever of unknown
origin,
I 5:127
radiologic
evaluation,
SA95:#259
SA94:#1
Outcomes,
92
and
quality
improvement,
14:208
Ovary,
SA94:#210
torsion,
13:183
Overaeration
lung,
15:162(abs)
Overdose
amitriptyline,
SA95:#34
cocaine,
15:89
Oximetry,
pulse,
SA94:#49
Oxybutynin,
antispasmodic,
I 6:22
Oxygen
desaturation,
sleep disorders,
13:1 16(abs)
saturation,
pulmonary
function
tests,
15:403
in newborn,
SA93:#256
toxicity,
16:209
Oxygenation,
cor pulmonale,
I 3:473(abs)
Oxylate
renal stones,
l5:80(abs)
Osteoporosis,
16:266
Osteosarcoma,
I 3:469
characteristics,
SA94:#292
Otalgia,
13:355;
SA93:#319
Otitis externa
characteristics,
tube
SA95:#57
SA95:#58
treatment,
SA93:#97
Otitis media,
14:320;
15:93;
16:17
acute
age distribution,
SA93:#1
17
manifestations,
SA93:#64
treatment,
SA93:#21
1 #220,
#284
,
P
Pain
abdominal,
14:67, 302; 16:448
back,
16:218
chest,
16:218
chronic,
l4:l67(abs);
16:218
knee, ankle injuries,
13:429
knee, referred
from hip, 13:157
limb,
16:218
management,
16:419;
SA93:#43
neuropathic,
16:218
psychosomatic
disorders,
I 5:448
recurrent,
16:218,
448
recurrent
abdominal,
16:218
504
referred,
SA93:#31
9
syndromes,
16:29
Palate,
submucous
cleft,
Pancreatic
insufficiency,
Papilledema
causes,
SA95:#166
increased
intracranial
I 5:241
Papillomatosis,
recurrent
16:37
Papular
acrodermatitis,
13:203
urticaria,
SA94:#284
Paracentesis,
abdominal
I 3:238(abs)
14:191
15:192
causes,
SA93:#44
cystic
fibrosis,
I 3:183
in infants,
SA93:#203
Pancreatitis,
13:32(abs)
characteristics,
14:302;
15:24
cystic
fibrosis,
I 5:192
laboratory
evaluation,
SA93:#220
mumps,
SA93:#210
Panic disorder,
13:381;
15:384
Pediatrics
i,i
Paralysis,
tick,
Paraquat,
poisoning,
Review
Vol.
pressure,
respiratory,
trauma,
I 6:223
16
14:41
No.
12
1
December
1995
I
S
Parasympathetic
nervous
system,
Pentamidine,
diagnosis,
SA94:#1
SA93:#62
Periodontitis,
474
Passive
smoking.
14:444
Pasteurella
infection,
I 3:394(abs)
Patella,
13:429
dislocation,
15:494(abs)
Patellofemoral
pain, 13:429
Pauciarticular
arthritis,
15:167;
SA93:#233
Paul-Bunnell
antibodies,
15:39
PCP, hallucinations,
14:466
Peak expiratory
flow rate. I 3:403;
15:403
Peak height
velocity,
SA94:#232
Pediatric
life support.
16:466
Pediculosis,
16:336(abs)
Peer
factors,
drug abuse.
13:314
relations,
after divorce,
16:306
Pellagra.
13:185
Pelvic
examination,
menstrual
inflammatory
disease.
13:216;
14:180: SA94:#200
contraception.
I 3:216
fever,
15:127
Penicillin,
16:83
activity.
SA93:#244
adverse
effects,
SA94:#55
allergy
alternative
therapy,
SA93:#1
testing,
SA93:#42
mechanisms
of action,
15:440
reactions,
14: l52(abs)
SA94:#1
Persistent
pulmonary
hypertension.
newborn,
l5:151(abs)
Pertussis,
I 3:438(abs):
16:37
cough.
l6:72(abs)
prophylaxis,
15:377
transmission,
Vol.
1
/6
No.
/2
I 3:283
treatment,
SA95:#1 67
vaccine,
15:433
contraindications,
SA93:#201
dose, SA93:#201
indications,
SA93:#221
Pervasive
developmental
disorder.
16:130,
168
Pesticide
poisons,
14:411
Petechiae,
13:269
causes,
14:215
tonsillopharyngitis.
15:185
uses. SA93:#244
Penis,
normal,
15:288(abs)
Review
1
15:15 l(abs)
Pelvic
i,i
15:31
Periorbital
swelling.
14:345;
16:163
Peripheral
alimentation,
14: 103; 15:78
Peripheral
brain
emergency
drugs.
16:229
quick facts on poisoning.
15:151
Peritoneal
lavage,
in splenic
injury,
15:391
Peritonitis
primary.
SA94:#1
86
secondary,
SA94:#21
7
Peritonsillar
abscess,
16:117;
SA95:#14
characteristics,
SA95:#256
cellulitis,
I 6: 1 17
Peritonsillitis,
16: 1 17
Permethrin
lice, 16:336(abs)
scabies,
15:110
Persistent
fetal circulation,
13:43
semisynthetic,
13
manifestations,
SA95:#1 96
Perihepatitis,
I 3:216
gonorrhea/chlamydia
infections.
SA94:#18;
SA95:#197
Perilymphatic
fistula.
15:115
Perinatal
infections.
14:251
Perineal
contact
dermatitis,
14:240
Periodic
breathing,
13:262;
14:51;
supraventricular
tachycardia,
14:273
Partial
complex
seizures,
13:305
Partial
thromboplastin
time,
13:163:
16:290
Parvovirus
aplastic
crisis,
15:2l2(abs)
erythema
infectiosum,
13:236(abs);
disorders,
SA94:#229
pirenzepine
therapy,
15:389
prevention.
SA94:#73
treatment,
15:389
Percentile
charts,
13:396(abs)
Perforation,
tympanic
membrane,
15:93
Periactin,
urticaria,
13:387
Pericarditis,
14: 153(abs);
SA93:#270
juvenile
rheumatoid
arthritis,
13:16
16:438(abs),
14:371
Peptic
ulcer disease.
16:257
characteristics,
14:313
Parathyroid
absence,
1 3: 197(abs)
Parent-child
centers,
13:64
Parenteral
alimentation,
14:103;
15:78
nutrition,
14:123,
3l2(abs)
total, SA94:#273
indications,
SA95:#225
Parenting.
15:354:
SA93:#86
Parinaud
syndrome,
15:348
Parotitis,
16:349
recurrent
juvenile.
16:349
suppurative.
16:349
Paroxysmal
crying.
virus.
December
1995
1
..
human
immunodeficiency
14:489
Pediatrics
S.
Pets. transmission
of infections.
13:283
Phagocytic
dysfunction.
14:226
Pharmacokinetics,
I 3:413
anticonvulsants,
SA95:#1 77
theophylline.
SA93:#7
Pharmacology.
in children.
I 3:413
Pharyngitis,
I 5:185
gonococcal.
laboratory
16:62:
SA93:#1
evaluation,
73
14:251;
SA93:#167
Pharyngoconjunctival
fever.
I 6:203
Phencyclidine. 13:273: 14:466
Phenobarbital
afebrile
seizures,
13:305
drug interactions,
SA93:#275
effect on activity
level. SA94:#203
effect on cognitive
functioning,
I 5:367(abs);
SA94:#203
febrile
seizures,
13:298
in neonate.
16:248
overdose,
SA93:#1
12
pharmacokinetics.
I 3:413
status epilepticus.
16:386
Phenothiazines,
movement
disorders,
15:391
Phenylketonuria,
I 5:359;
Phenytoin.
SA93:#1 94
afebrile
seizures,
13:305
effect on cognitive
functioning.
15:367(abs)
pharmacokinetics.
13:413
seizures,
16:248
status epilepticus.
16:386
Pheochromocytoma.
14:169
Phobia,
15:384
Physical
abuse.
cutaneous
signs,
SA93:#288
Physical
growth.
assessment.
13:88
Pica,
16:433
Pickwickian
syndrome.
14:337
Pierre
Robin
sequence
anomalies
craniofacial,
I 6:424(abs):
SA95:#1
35
ear, SA95:#1 35
renal, SA95:#135
management.
SA93:#1
78
Pilomatrixomas,
I 3:371
Pilonidal
dimples.
13:262
Pimozide,
Tourette
syndrome.
I 3:37(abs)
Pink eye. 16:203
Pinworms,
14:141:
l6:247(abs)
diagnosis,
SA95:#1 23
treatment,
SA95:#123
Piperazine,
pinworms.
l6:247(abs)
Pirenzepine,
peptic
ulcer disease,
15:389
Pityriasis
rosea,
15:159(abs):
SA94:#240,
PKU-see
#264
Phenylketonuria
505
I
.
.
S
#{149}
Plague,
cervical
adenopathy,
I 5:276
PIano valgus,
l4:50(abs),
395
Plasma
volume,
14:70
Platelet
count,
bruising,
14:215
Pleural
effusion,
l6:79(abs)
fluid, evaluation,
SA94:#81
thickening,
16:79(abs)
Pneumatoceles,
SA93:#267
Pneumatoscopy,
I 3:355
Pneumatosis
intestinalis,
15:338
Pneumococcal
pneumonia,
16:117
vaccine,
SA93:#276
postsplenectomy.
I 5:274(abs)
sickle cell disease,
15:136(abs)
Pneumococcus,
16:117
bacteremia,
14:366(abs)
fever,
15:127
Pneuinocvstis
carinii
in immunocompromised,
SA94:#1
14:226;
35
pneumonia,
management,
14:371
prophylaxis,
SA93:#10;
SA94:#164
risk factors,
SA95:#79
Pneumomediastinum,
I 3:398(abs)
Pneumonia
chlamydial.
SA95:#21
1
complications,
SA93:#267
immunodeficiency.
14:226
laboratory
diagnosis,
14:251
mycoplasmal,
SA93:#279
neonatal,
SA94:#1 56
pneumococcal,
16:117
prevention.
SA95:#21
4
prophylaxis,
SA93:#10
radiologic
findings,
in newborn,
SA93:#1
07
recurrent,
14:371
salicylate,
SA95:#95
staphylococcal,
SA93:#267
Pneumothorax,
SA93:#278;
14:237
15:192
1 3:398(abs)
Point-counterpoint.
324;
15:93, 456;
13:36:
14:101,
16:304
Point of clarification:
teething:
is it
painful?,
16:56
Poison
ivy. 14:240
Poisoning, 13:273; 14:411; SA93:#49
carbon
monoxide,
1 3:6(abs),
295;
SA95:#283
caustic
substances,
SA93:#6
coma,
15:204
peripheral
brain, quick facts,
15: 151
prevention,
SA93:#251
Poliomyelitis
vaccine,
Polyarteritis
13:203,
nodosum,
245
506
15:433
viral
hepatitis,
‘1’.
Polycystic
kidney
disease
characteristics,
SA93:#298
evaluation,
SA95:#142
Polycystic
ovary syndrome,
13:43;
SA93:#94
Polycythemia,
cyanotic
heart disease,
13:379
Polydipsia,
I 5:137
Polyhydramnios,
13:50;
15:338
Polymerase
chain reaction
human
immunodeficiency
virus,
I 4:38(abs)
Lyme disease,
15:219
prenatal
diagnosis,
I 3:138
Polymyalgia
rheumatica,
viral
hepatitis,
13:203
Polymyxin.
mechanism
of action,
15:440
Polyps
juvenile,
SA94:#242
nasal, SA93:#245,
#287
rectal,
SA93:#294
Polyuria,
15:137
Port wine stains
glaucoma,
SA95:#99
laser treatment,
SA95:#226
Positive
pressure
ventilation,
I 5:255
Positron
emission
tomography.
urethral
valve,
.
555
I
.
S
disease,
16:426
Prolapse,
rectal,
associated
conditions,
SA95:#282
Prolonged
QT interval,
13:469;
15:437
Prolonged
rupture
of membranes,
infection,
SA94:#303
Prophylaxis,
antimicrobial,
I 5:377
endocarditis,
16:148
recurrent
otitis media,
SA94:#70
rifampin,
I 3:354(abs)
sexually
transmitted
diseases,
evaluation,
SA95:#274
Poststreptococcal
nephritis,
laboratory
findings,
SA93:#241
Posttraumatic
stress syndrome,
I 5 :I6
Potassium
acidosis,
SA95:#20
iodide,
13:152
PPD tuberculin
skin test, 13:343;
14:263(abs)
Prader-Willi
syndrome,
14:337;
SA93:#1
30
Propionibacterium
I 5:47
acnes,
Propionic
acidemia,
15:359
Propranolol
arrhythmia,
15:437
Graves
disease,
15:417
migraines,
15:94
pharmacokinetics,
I 3:413
Proptosis,
16:163
Propylthioracil, I5:4 17
Prostaglandins,
13:83
ulcer disease,
SA94:#73
Protective
equipment,
sports,
69
Preauricular
tags, 13:371
Precocious
puberty,
SA95:#250
Pregnancy
adolescent,
l4:l16(abs);
15:32
prevention,
15:32
amenorrhea,
I 3:43
cocaine
use, 15:89
diagnosis,
SA94:#21
3
ectopic, 13:216
rubella
vaccine,
l6:432(abs)
Premature
rupture
of membranes,
infection,
SA94:#303
Premature
ventricular
complexes,
15:437
Prenatal
diagnosis,
13:138,
334
DNA,
13:138
metabolic
disease,
SA94:#1 5
PREP, Pediatrics
Review
and
Education
Program,
pickles,
pizza,
and (commentary),
13:3
Pediatrics
.
Prepubertal
children
and athlete’s
heart,
13:15 l(abs)
Preschool
language
milestones,
I 5:41 2(abs)
Preterm
infant
anemia,
15:175
definition,
13:262
fluid therapy, 14:103
immunization,
SA95:#255
spastic
diplegia,
SA95:#78
vs low birthweight,
SA95:#64
Prevention
of
infection,
prophylaxis.
15:377
sports
injuries,
16:184
Preventive
counseling,
15:485
Primary
care, chronic
physical
disorders,
I 3:224
Problem
definition,
16:448
Proctitis,
sexually
transmitted
diseases,
14:180
Progressive
central
nervous
system
13:248
Posterior
SA93:#1
SA94:#279
chest trauma,
cystic
fibrosis,
spontaneous.
S
13:422;
14:424
Protein
digestion,
preterm
infants,
14:123
malnutrition,
14:95
requirements,
in preterm
infants,
SA95:#48
restriction,
in renal disease,
SA93:#309
Proteinuria
exercise-induced,
SA93:#1 31
hematuria,
15:102
nephrotic
syndrome.
14:30
transient,
SA93:#1 31
Prothrombin
time, 13:163; 16:290
Pruritus,
atopic
dermatitis,
15:327
in
Review
Vol.
16
No.
12
December
1995
I
I
\
‘
Psychotropic
medication,
I 5:5
Ptosis,
congenital
vs acquired,
Pseudomembranous
colitis
laboratory
evaluation,
SA93:#78
management,
SA93:#48
Pseudomonas,
treatment,
SA93:#257
Pseudostrabismus,
13:7
Psilocybin,
hallucinogens,
14:466
Psoas abscess,
16:458
Psoriasis,
SA94:#27
diaper
area, 16:142
Psoriatic
arthritis,
SA94:#27
Psychoeducational
testing,
I 5:480;
SA93:#53
Pubarche,
15:39
Pubertal
development,
female,
15:39
Puberty,
16:243;
SA93:#246
constitutional
delay.
SA94:#40
delayed,
SA93:#32;
SA94:#237
Turner
syndrome,
SA95:#82
in boys,
13:5(abs)
precocious,
I 4:336(abs);
SA94:#246;
SA94:#221
Psychological
assessment,
problems,
SA95:#1
Tanner
SA94:#86,
I 4:455
adolescent
“loner”,
SA93:#87;
#224
Pulmonary
disease,
exercise
intolerance,
I 3:474(abs)
edema
drugs for treatment,
16:229
noncardiac,
14:163
function
scoliosis,
SA94:#91
tests, 13:403;
15:403
Pulse oximetry,
15:403
Pulsus
paradoxus,
13:403
75
tests,
14:455;
15:473;
16:338
Psychosocial
adjustment,
I 3:224
development,
13:88
problems,
16:448
Psychosomatic
complaints,
16:29
disorders,
15:448;
SA94:#243
Psychostimulant
medications,
14:455
Quinolones,
Quality
improvement,
16:273,
311
SA95:#250
staging.
Q
mechanism
Puncture
wounds,
I 3:257;
16:380;
SA93:#88
Purpura
causes,
14:215
Henoch-Schoenlein
purpura,
13:130
idiopathic
thrombocytopenic,
14:215
vasculitis,
SA95:#1 65
Pyelonephritis,
16:190
etiology,
SA95:#1 08
radiologic
evaluation,
SA95:#1
therapy,
SA93:#269
Pyloric
76
stenosis
characteristics,
laboratory
15:24,
SA93:#226;
web,
Pyogenic
Pyrantel
338
evaluation,
SA94:#85
SA94:#5
granuloma,
pamoate,
SA93:#1
Pyrazinamide,
Pyridoxine,
I 3:371
16:247(abs);
15
tuberculosis,
seizures,
248
I 3:343
of action,
QT interval,
15:437
14:208;
15:440
prolonged,
I 3:469;
R
Rabies,
I 4:280(abs)
animal
carriers,
SA93:#259
vaccine,
indications
for use,
SA94:#289
Radial
artery puncture,
use of
mannequins
in training,
13:244
Radiography,
lymphadenopathy,
16:456(abs)
Radionuclide
scan, vesicoureteral
reflux,
l3:279(abs)
Radius,
absence
of and
thrombocytopenia,
SA95:#54
Rapid
diagnostic
procedures,
16:62
Rash
niacin
overdose,
14:433
penicillin
reactions,
14:152(abs)
RAST
(radioimmunoassay),
allergy,
16: 178
Reactive
airways,
I 3:403
Reading
development,
I 3:231
disability,
13:231
Receptors,
autonomic,
14:489
Rectal
biopsy,
Hirschsprung,
16:5
bleeding
causes,
SA93:#294
evaluation,
14:352;
SA95:#63
Pediatrics
in Review
Vol.
16
No.
/2
juvenile
polyp,
SA93:#294;
SA95:#63
manometry,
14:447
prolapse,
15:192;
SA95:#282
Recurrent
abdominal
pain, 13:397(abs);
14:67, 313
infections,
IgG subclass
deficiency,
14:291
pain, 14:l67(abs)
respiratory
infections,
immunodeficiency,
14:226
Red urine,
15:102
Reflux
gastroesophageal,
14:155;
SA93:#307;
SA94:#1
69
nephropathy,
I 3:279(abs)
vesicoureteral,
16: 190; SA93:#31
1
Regurgitation,
15:24
Rehydration,
15:461
oral, SA93:#291
; SA94:#1
71
Relaxation
for pain, 16:2 18
Remarriage,
16:306
Renal
anomalies,
SA93:#1 42
disease
protein
intake,
SA93:#309
December
1995
systemic
lupus erythematosus,
14:194;
SA94:#7
failure
amphotericin
B, 16:123
evaluation,
16:101;
SA95:#75
hemolytic-uremic
syndrome,
14:218
Henoch-Schoenlein
purpura,
13:130
management,
14:103;
16:137;
SA93:#1
96
prerenal
and intrinsic,
15:253(abs)
hydrogen
ion regulation,
stones,
l5:80(abs),
102,
structural
abnormalities,
SA95:#1
SA95:#65
495
hematuria,
26
tubular
acidosis,
13:391
hypokalemia,
SA94:#251
laboratory
evaluation,
SA93:#222;
SA94:#251;
SA95:#60
proximal
vs distal,
SA95:#60
tumor.
13:25
vascular
hypertension,
14:169
Renin,
measurements,
SA94:#67
Repetitive
microtrauma,
16:458
Repetitive
movements,
16: 1 30, 168
507
I
....
in infants. 13:16
Reproductive
health.
14:180
Resilience,
after divorce,
16:3()6
Respiratory
distress
syndrome.
14:163:
16:209
adult.
14:163
choanal
atresia,
l6:475(abs)
neonatal.
16:209
pulmonary
function
testing.
15:403
sleep disturbances.
13: 1 16(abs)
papillomatosis.
syncytial
16:37
virus.
laboratory
I
,.S..
14:134:
16:62
diagnosis.
14:251
transmission.
SA93:#263
tract disease.
lower,
chest
radiographs.
13: 196(abs)
Resuscitation,
16:466
neonatal,
15:255;
SA95:#237
Reticular
agenesis.
14:226
Reticulocyte
counts,
15:175.
299
Retinal
detachment,
13:422
Retinitis,
human
immunodeficiency
virus, 14:371
Retinohlastoma,
13:7
Retinol,
13:185;
16:358(abs)
Retinopathy
of prematurity.
Retrolental
fibroplasia,
I 6:50
Retropharyngeal
abscess,
14:19
characteristics.
SA94:#1
76;
Rifampin
mechanism
ofaction,
15:440
prophylaxis.
13:283,
354(abs)
tuberculosis,
13:343
Ringworm.
I 3: 152
Risk taking,
pubertal.
16:243
Rock music,
13:144
Rocky
Mountain
spotted
fever.
13:269
characteristics,
SA95:#90
Roseola
characteristics,
SA94:#1 97;
SA95:#256
treatment.
SA94:#262
Retrovirus
infection,
14:371
Rett syndrome.
15:473;
16: 130,
168;
SA94:#10
Reye syndrome.
15:24: SA93:#14
Rhabdomyolosis.
15:495
Rheumatic
fever,
14:272(abs)
characteristics,
SA94:#120,
#261
prophylaxis.
15:377
Rhinitis
allergic.
13:323:
SA93:#300;
SA95:#112
etiology.
SA95:#1
12
Rotavirus
infections,
15:461
characteristics
of stools,
SA95:#3
laboratory
evaluation,
SA93:#305
transmission,
13:283
Rubella
health
care workers.
SA94:#185
immunization.
16:432(abs):
SA94:#295
chronic,
SA94:#33
cocaine
abuse,
14:361
Rhinovirus,
transmission,
13:283
Rhythm
disturbances.
cardiac,
14:273;
Ribavarin
Rickets,
hepatic
15:437
therapy.
13:185
disease,
in preterm
16:50:
risk factors,
SA95:#6,
#88
Rickettsia,
petechiae.
13:269
14: 134
SA94:#115,
SA94:#128
Rumination,
infants, 14:123:
#185
13:174:
15:24:
SA94:#3
SA95:#88
SA93:#17
S
Safety.
in adolescence.
Salicylates
poisoning,
13:33;
15:485
14:411:
15:151
Reye
syndrome,
SA93:#1 4
infections,
15:461 ; 16:283
Salpingitis.
13:216;
SA94:#18
Salt wasting.
SA94:#299
Sandifer
syndrome.
I 3:174
Sarcomas.
13:371
Scahies.
15: 1 10
Scalded
skin syndrome.
staphylococcal
toxin,
SA95:#70
Scarf
sign.
in infant.
16:41 1
Scheuermann
disease.
kyphosis.
Salmotiella
SA95:#229
Schizophrenia
characteristics,
SA95:#1
childhood,
SA94:#45
School
absenteeism.
I 6:218
exposure
to infections,
failure,
14:214(abs);
72
16:283
16:325
problems
evaluation,
risk factors,
performance.
508
Seizures
absence
syphilis.
developmental.
Development
lead, 13:461
preschool
and
84
SA94:#1
78
SA95:#127
14:455
SA94:#1
SA94:#42
43
treatment,
SA94:#2
hypernatremia.
hypocalcemia.
performance.
SA94:#21
SA95:#199
infantile
spasms.
medical
record
1
SA93:#4,
review,
#106
13:75
metabolic
causes,
SA95:#199
neonatal,
16:248;
SA95:#199
petit mal. SA93:#103
status epilepticus,
16:386
theophylline.
SA95:#138
Selenium
deficiency.
14:123
scoliosis,
14:297
tests. developmental.
16:338
vision
problems
(commentary).
13:4; l6:77(abs)
Scrotum, acutely painful. 13:295
Scurvy.
13:185
Seat belts,
l4:244(abs)
Sebaceous
cysts.
13:371
Seborrheic
rash, histiocytosis.
I 5: 1 17
Sedatives,
13:381
Seizure
activity.
diagnosis,
SA94:#1
13:305;
SA94:#143
diagnosis.
SA94:#169
diarrhea,
SA93:#95
fehrile,
I 3:298
epilepsy.
SA95:#276
Denver
Test, SA95:#262
school
mal).
03;
afebrile,
13:305
behavioral
problems.
15:366
cardiac
causes,
13:469
complex
partial.
13:305:
Screening
congenital
(petit
SA93:#1
SA95:#44
prevention.
13:64
health,
management
of asthma,
14:39 1
learning.
tests.
16:338
learning
phobia.
16:57
readiness,
14:4: 16:338
refusal,
16:29, 57
Schwachman
syndrome.
15:192
Scleroderma,
16:49(abs)
localized
vs systemic.
SA95:#1
morphea.
SA95:#1 84
Scoliosis,
14:297
etiology.
SA95:#86
pulmonary
function,
15:403:
SA94:#91
Sensori
neural
absence
hearing
Separation
of otitis media,
15:115
loss, 14:43
anxiety.
13:16:
16:57:
SA94:#30
disorder,
16:57
69
1’(di(Itri(5
ill
Resiess
Vol.
16
No.
12
!)ecember
/995
I
:%k4 ;r;
5
Sepsis
bacterial.
97
disease,
newborns,
14:436
13:163:
14:262
purpura.
13:269
sickle cell disease,
I 5: 136(abs)
splenectomy.
15:274(abs)
very-low-birthweight
infants,
16:3 16
Septic
arthritis,
16:458;
SA94:#1 27;
SA95:#21
familial,
8
abuse.
l5:42(abs),
adolescents,
SA93:#135;
SA94:#205
maturation,
13:43, 88; 14:401:
16: 158
orientation,
14:401
Sexuality.
13:144;
14:401
Sexually
transmitted
diseases,
14:180:
16:12
antibiotic
prophylaxis.
SA93:#1 30
drug abuse,
15:42(abs)
pelvic
inflammatory
disease,
13:2 16
sexual
abuse,
13:443
symptoms
of, SA95:#132
treatment
of Chlainvdia,
SA93:#225
treatment
of gonorrhea.
SA93:#248
vulvovaginitis,
14:141
Sizigella
species,
SA93:#297
dysentery.
15:461
transmission,
13:283:
16:283
Shingles.
13:107:
SA93:#234
Shock
cardiogenic.
13:358(abs);
16:155,
347
characteristics,
SA93:#89,
#129
evaluation,
SA95:#230
neonatal
sepsis.
SA93:#89
treatment.
SA95:#1 60
characteristics,
SA93:#39;
SA94:#259;
Pediatrics
iii
Review
/6
No.
12
SA93:#276
SA94:#282
sequestration
crisis,
I 3:33
treatment
of fever, SA95:#258
Silver
nitrate,
eye prophylaxis.
14:423
Single
photon
emission
tomography.
I 3:248
Sinusitis,
14:345
computed
acute
fever,
15:127
microbiology,
SA95:#201
treatment,
SA94:#1 62
chronic
associated
conditions,
SA95:#80
cystic fibrosis,
SA95:#124
immunodeficiency.
14:226
Size, penile.
micropenis.
l5:288(abs)
Skeletal
mineralization,
lowbirthweight
infant.
14:123
Skin
disease,
atopic
dermatitis.
I 5:327
infections,
streptococcal.
SA93:#1
63
testing
allergy.
16:178:
SA93:#42
infancy,
SA95:#1 64
penicillin.
SA94:#212
Skull fractures. 14:389; 15:213:
SA94:#88
SA95:#128
Vol.
15: 136(abs);
inheritance,
13:138
neurologic
complications.
SA93:#47
penicillin
prophylaxis,
SA95:#273
pneumococcal
vaccine,
SA93:#276
prenatal
diagnosis.
I 3:334:
sexual
485
behavior,
I 3:295
syndrome,
SA95:#19
infections,
1)eee,nber
/995
disturbance,
respiratory
13:1 16(abs)
patterns.
position.
infant.
sudden
conditions.
SA94:#278
infant death
14:83
problems,
13:16: SA93:#166
Slipped
capital
femoral
epiphysis.
13:157:
SA93:#44
SA93:#208
Abuse.
disease,
Sialolith,
16:349
Sibling
rivalry.
13:72
Sickle
cell disease
acute chest syndrome.
SA94:#58
anemia,
15:175
aplastic
crisis,
SA94:#136
characteristics,
SLE-See
systemic
lupus
erythematosus
Sleep
apnea,
16:17
decreased
ventilation.
cor
pulmonale.
I 3:473(abs)
syndrome.
15:161(abs)
inflammatory
bowel
SA95:#66
Shunt
malfunction,
13:295
ventriculoperitoneal.
Shwachman-Diamond
vs toxic synovitis,
SA94:#111
Septic
shock.
treatment,
SA94:#1 93
Sequestration.
bronchopulmonary,
crisis,
13:33
Serum
osmolarity.
14:70
Serum
sickness
hepatitis,
I 3:203,
245
penicillin,
14: 152(abs)
Sex chromatin
anomalies
Klinefelter
syndrome
(XXY).
13:435:
SA94:#187
speech
and language
development.
I 3: 1 19(abs)
Turner
syndrome
(XO),
13:43;
Sexual
abuse-see
Sexual
activity.
drug
I
cold urticaria,
15:289
drugs for treatment,
16:229
neurogenic,
SA93:#1 16
septic,
SA93:#39
Short bowel
syndrome.
I 3:185
Short stature
boys.
l3:5(abs)
causes,
SA94:#56;
SA95:#187
evaluation,
SA94:#40,
#43, #56,
#62; SA95:#16
characteristics,
SA93:#1
liver
:‘
16:458
Small
for gestational
age infants,
I 6:354(abs)
Smegma.
SA94:#69
Smog.
asthma.
13:403
Smoke,
allergy
prevention.
15:301
Smoking
in adolescence,
16:243
asthma.
13:403
Snoring.
sleep apnea.
14:445
Social
development.
I 6: 158
skills training.
Socioeconomic
Sodium
balance.
fractional
16:12
class,
16:396(abs)
14:70
excretion.
SA93:#1
27;
SA95:#75
total
Sodium
body.
SA93:#127
valproate.
13:298.
305
Soft neurologic
signs.
13:231
Soiling.
encopresis.
14:447
Solid foOds.
15:321
Somogyi
phenomenon.
diabetes,
15: 137
Sonography.
prenatal
diagnosis.
13:334
Sorbitol,
chronic
diarrhea,
I 3:399(ahs)
Soy formulas.
15:321:
16:107
Spasmodic
croup.
14: 19
Spastic
diplegia.
16:41 1
prematurity.
SA95:#78
Special
education,
14:4: 16:325
Speech
awareness
threshold,
SA94:#1 48
development.
I 6:91
preschool
milestones.
I 5:4 12(abs)
problems.
XXY karyotype.
13:1 l9(abs)
Spherocytosis.
hereditary.
SA93:#1 39
Spina hifida,
15:480
occulta,
SA95:#221
Spinal
cord
disorders,
14:364
injury.
l6:28(abs):
SA93:#116
lesion.
14:1 17
acute leg weakness,
SA95:#1
11
characteristics,
SA95:#1 11
509
..
Spirochete,
Lyme disease,
15:167
Spirometry,
15:403
Spitz nevi, 13:371;
16:365
Spleen,
injury/rupture,
15:391;
SA94:#300
Splenectomy
administration
of vaccines,
I 5:274(abs);
SA94:#84
Hodgkin
disease,
SA95:#1
10
infectious
complications,
SA95:#1 10
perioperative
management,
I 5:274(abs);
SA94:#84
red cell disorders,
15:274(abs)
Splenomegaly,
I 3:25
Epstein-Barr
virus,
15:63
hereditary
spherocytosis,
15:245(abs)
thalassemia,
13:55
Spondylitis,
ankylosing,
14:117
Spondylolithesis,
I 6:458
Sporotrichosis,
I 3:152
Sports
exercise
intolerance,
13:474(abs)
injuries,
16:184
head trauma,
15:2 13
medicine,
14:424;
16:184
use of goggles.
13:422
use of mouthguards,
SA95:#1 98
Sprain,
ankle,
13:429;
14:424
Stabilization,
very-low-birthweight
infants,
16:316
Stanozolol,
angioedema,
13:387
Staphylococcal
osteomyelitis,
16:380
scalded
skin syndrome
(SSSS).
pathogenesis,
SA95:#70
Staphylococcus
aureus,
SA93:#292
coagulase
production,
SA95:#35
transmission,
I 3:283
Starch
absorption,
in infancy,
SA95:#267
Status
epilepticus.
13:298,
305; 16:386
causes,
SA95:#188
neonatal,
16:248
treatment,
SA94:#1 3
Steroids
anabolic,
14:424
Henoch-Schoenlein
purpura,
I 3:130
nephrotic
syndrome,
14:30
Stevens-Johnson
syndrome
erythema
multiforme,
SA95:#159
sulfonamides,
SA94:#1 24
Stimulant
medications,
16:325
Stings
hymenoptera.
16:355(abs)
insect,
SA93:#218
Stones,
renal,
15:80,
102, 495
Stool, neonatal
first, 15:319(abs);
16:5
510
1
:
:
.
Stooling,
frequency
in infants,
SA93:#1 46
Strabismus,
13:7; 15:497(abs)
evaluation,
SA95:#271
torticollis,
14:433
Strawberry
hemangioma,
13:371;
15:266;
SA95:#203
Street drugs,
l5:372(abs)
Streptococcal
antibodies,
16:278(abs)
infection
in infants,
15:276
pharyngitis,
rapid detection,
SA95:#1 68
prophylaxis,
rheumatic
fever,
:.,::,
depressant
substances,
13:381
depression/suicide.
14:380
diagnosis
and treatment,
13:314
drugs,
SA93:#112,
#128, #312;
SA95:#50
hallucinogens,
street drugs.
Sucking
SA93:#84
15:372(abs)
in neonates,
14:123
non-nutritive,
15:377
skin infections,
SA93:#163
tonsillopharyngitis,
15:185
Streptococcosis,
I 5:276
Streptococcus
group A beta-hemolytic,
I 3:283;
15:185;
16:62, 283
group B
intrapartum
management.
SA95:#73
neonatal
sepsis,
15:262
transmission,
SA93:#73
pneumoniae,
16:117
characteristics,
SA93:#1 88
otitis media,
14:320
resistant
to penicillins.
16:357(abs)
pyogenes
(GpA strep),
13:283;
15:185;
16:62, 283
Streptomycin,
tuberculosis,
I 3:343
Stress
divorce,
16:306
family,
16:243
fractures,
16:458
-related
behavior,
SA94:#243,
#252
test, SA93:#30
Stridor
congenital.
evaluation,
SA93:#93,
#282
croup,
14:19
recurrent
respiratory
papillomatosis,
16:37
retropharyngeal
abscess,
I 3: 1 13
Strychnine,
13:273
Sturge-Weber
syndrome,
I 5:266:
SA93:#1 34
Stuttering,
16:91
Subcutaneous
tumors,
I 3:371
Subdural
effusion,
meningitis,
I 4: 1 1;
SA95:#265
hematoma,
I 5:394;
SA95:#40
Sublingual
frenulum,
l6:345(abs)
Subluxation,
hip. 16:299
Submucous
cleft palate.
16:424(abs)
Substance
abuse,
I 5:485;
16: 12, 197
alcohol,
SA93:#90,
#312
cocaine,
15:89; SA94:#80
Pediatrics
l6:73(abs)
thumb,
16:73(abs)
Sudden
Infant
Death Syndrome,
14:51, 83
apnea/bradycardia.
I 4: 100(abs)
recurrence,
I 4:94(abs)
Suicide,
13:144;
14:380;
15:485
attempts.
14:380
risk factors,
SA94:#93
Sulfadiazine,
15:377
Sulfasalazine,
14:475
Sulfasoxizole,
I 5:377
Sulfonamides,
15:440
prophylaxis.
otitis,
I 3: 199(abs)
side effects,
SA94:#124
Support
groups,
death,
16:419
Suprapubic
bladder
puncture,
I 6:190;
SA94:#209
Supraventricular
tachycardia,
15:437
Surface
area, in newborn,
I 3:262
Surfactant,
16:209
Surgery
corticosteroids,
13:403;
16:266;
SA93:#76
psychological
preparation,
13: 126(abs)
Surgical
abdomen,
in children,
14:302
Sutures,
Swenson
cranial,
16:1 15(abs)
procedure,
Hirschsprung
disease,
16:5
Sweat
electrolytes,
in cystic
13: 183
sports,
14:424
testing.
15:192
Swimming
pool,
SA95:#1
Sydenham
Sympathetic
Syncope
Syndrome
safety
measures,
31
chorea,
SA94:#131
nervous
system.
arrhythmia,
cardiac
fibrosis,
14:489
15:485
causes,
13:469
of inappropriate
antidiuretic
hormone
(SIADH),
SA93:#238
secretion
Synovitis
toxic, 15:201
transient,
Syphilis,
16:458
14:180
congenital,
15:42(abs);
SA94:#1
7,
December
/995
#42
drug
i,i
Review
abuse,
Vol.
15:42(abs)
/6
No.
/2
I
I
false-positive
test in systemic
lupus,
14:281
secondary
vs pityriasis
rosea,
15: l59(abs)
serologic
tests,
sexual
abuse,
14:281:
Syringomyelia,
Syrup
of ipecac,
Systemic
lupus
14:194,
characteristics,
complications
16:62
13:443
15:480
SA93:#6;
SA94:#144
erythematosus.
281
diagnostic
criteria,
glucocorticoids.
laboratory
evaluation,
SA95:#1
SA94:#1
of therapy.
32
SA95:#42
renal
14:281
16:266
SA93:#1
51;
48
disease,
15:102:
SA94:#7
T
Tachycardia
hyperthyroidism.
15:417
paroxysmal
supraventricular.
14:273
supraventricular.
manifestations,
SA95:#33
Tanner
stages,
SA93:#87;
SA94:#86,
#224
Target
Taurine
joint,
hemophilia,
requirements,
16:290
in preterm
infants,
14:123
Tay-Sachs
disease,
characteristics,
SA93:#1 38
Tazobactam,
16:83
Technetium
scans
osteomyelitis.
16:380
reflux nephropathy,
13:279(abs)
Technical
tips
taste of children’s
medicine,
serologic.
13:195
violence,
15:16
Temper
tantrums,
15:366
Temperament.
SA94:#254
Temperature
regulation.
in very-lowbirthweight
infants,
16:306
Tension
headaches,
15:94
Teratogens,
13:364
acne treatment,
SA95:#1 81 #280
coumadin,
SA95:#186
rifampin,
I 3:354(abs)
vitamin
A derivatives,
SA95:#181,
#280
Terfenadine,
13:323
Terminal
illness,
reactions,
I 6:419
,
Testes
abnormalities
in Klinefelter
syndrome.
13:435
retractile
vs undescended,
SA95:#87
self-examination.
13:295:
13:l15(abs)
14:302;
15:286,
455(abs)
undescended
age for surgery,
risk
of neoplasia,
SA95:#275
15:272:
14:2 18
SA94:#77
Pediatrics
16:62
in Review
Vol.
/6
No.
12
December
/995
in neonates.
13:163
sepsis.
13:269
systemic
lupus erythematosus.
14: 194
Thrombosis,
deep venous
and
congenital
coagulation
disorder,
SA95:#74
Thrush
oral, SA93:#3
recurrent,
SA95:#1 79
Thumb
sucking.
13:16:
16:73(abs)
Thymic
aplasia.
immunodeficiency,
14:226
syphilis,
16:62
tularemia.
16:62
Tetanus
toxoid
administration,
15:433
boosters,
13:257
prophylaxis,
SA94:#1
#271
vaccine,
SA93:#1 25
Tetany.
13:185
Tetracycline
effect on teeth, SA94:#281
mechanism
of action,
15:440
ophthalmic
ointment,
14:423
use in children,
SA94:#281
Thalassemia,
13:55
anemia,
in infancy,
15:175
minor,
anemia,
SA95:#130
Thelarche,
15:39
Theophylline
asthma,
13:403
half-life,
SA94:#32
hypoalbuminemia,
SA93:#219
metabolism,
SA94:#94
overdose.
13:273:
14:411;
15:151
pharmacokinetics,
13:413;
SA94:#32,
#94
seizures,
SA95:#138
status epilepticus,
16:386
toxicity.
16:333;
SA93:#219;
SA94:#25;
SA95:#138
drug interactions,
13:113
Therapy
behavioral,
15:5
cognitive/behavioral,
I 5:5
Thrombocytopenia
absent
radius
syndrome.
SA95:#54
causes,
14:215
evaluation,
16:226
hemolytic-uremic
syndrome,
,
trapped
penile
foreskin,
14:140
use of mannequins
in training,
I 3:244
Teenage
pregnancy.
14:1 16(abs);
15:32
Teething.
16:56(point
of clarification)
Television,
13:144
torsion,
versus
retractile,
SA95:#87
Testicular
feminization
sydrome.
15:39
tumor,
13:1 15(abs)
Testosterone,
pubertal
delay,
I 3:5(abs)
Tests
antigen
detection,
16:62
brucella,
16:62
legionella,
16:62
leptospires.
I 6:62
Lyme arthritis,
16:62
Thymus
absence,
DiGeorge
syndrome.
I 3: 197(abs)
Thyroglossal
duct cysts.
I 3:371:
14:481:
SA95:#69
Thyroid
disorders
hyperthyroidism.
hypothyroidism,
stimulating
hormone,
tumor,
15:276;
Thyroiditis.
I 5:417
autoimmune,
15:417
I 5:227
15:417
I5:227
Hashimoto,
14:481:
15:227
lymphocytic,
I 4:481
thyroid
masses.
14:481
Thyromegaly.
I 4:481
Thyrotoxicosis.
15:417
Tibial
torsion,
14:395
Ticarcillin,
16:83
use, SA93:#257
Tick
-borne
virus,
16:353(abs)
Lyme disease,
15:167
paralysis.
16:223
Tics, Tourette
syndrome,
I 3:37(abs)
Tinea
capitis.
13:152
characteristics,
SA95:#27
treatment.
SA94:#296
corporis.
13:152:
SA93:#250
crusis,
13:152
pedis.
13:152
vs atopic
dermatitis,
SA95:#247
versicolor,
13: 152; SA93:#79
Tobacco,
nicotine,
14:275
Tocopherol.
13:185
Toilet training. 16:5, 448: SA95:#234
Toileting
program.
encopresis.
14:447
Tongue-tie.
I 6:345(abs)
51/
I
.
management,
Tonsils,
.
.
S
,
5:
SA95:#4
16:17
Tonsillar
hypertrophy,
cor
I 3:473(abs)
Tonsillectomy.
indications,
SA95:#1 13
Tonsillitis.
16: 17;
I 5:185
Tonsillopharyngitis.
15:185;
Tooth,
Torsion
pulmonale,
diagnosis,
exudative,
SA93:#258
dental
care, 15:311
of testis,
I 3:295;
15:286,
14:302;
455(abs)
Torticollis
congenital.
14:433
causes,
SA93:#180
gastroesophageal
reflux,
13:174
Total parenteral
nutrition,
SA94:#273
jaundice,
15:233
Total quality
management.
14:208
Tourette
syndrome,
13:37(abs);
SA93:#204,
#281
inheritance
pattern,
I 3:460(abs)
treatment,
SA95:#2
Toxemia
of pregnancy,
14:1 16(abs)
Toxic
exposures,
poisons.
14:41 1
shock syndrome.
SA94:#290
synovitis,
SA94:#1
11
Toxicity,
theophylline,
SA93:#219;
SA94:#25
Toxicology
SA93:#1
Toxocara
screening.
2
infections,
urine,
I 6:433
Toxoplasmosis
cervical
adenopathy,
15:276
congenital,
complications.
SA93:#1 1
treatment,
SA95:#68
Trace elements,
I 6:352(abs)
Tracheitis,
bacterial,
reactions,
I 5: 122(abs)
-related
hepatitis,
13:245
thalassemia,
13:55
Transient
hypogammaglobulinemia,
neonatal
pustular
melanosis,
14:19:
SA94:#227
Tracheoesophageal
fistula.
13:50:
15:338
Tracheomalacia,
characteristics,
SA93:#59;
SA94:#1 52
Transaminase
levels,
rhabdomyolosis,
15:495
Transcranial
Doppler
imaging.
13:248
Transfusion
SA93:#1
,
,
13:35(abs);
15:473
cardiac
disease,
14:488(abs);
SA94:#206
characteristics,
SA94:#1 68
duodenal
atresia,
SA95:#37
Tropical
pediatrics,
14:95
Truancy,
16:57
Trypsinogen
deficiency,
15:192;
14:226
84
SA93:#44
Tube feedings,
15:78, 8I(abs)
complications,
SA94:#35
composition,
SA93:#1 57
Tuberculin
skin test, 13:343;
40
SA94:#142,
Tranquilizers,
13:381
Transudate,
pleural,
16:79(abs)
Trauma
cervical
spine, SA94:#9
chest,
14:237
eyes,
13:422
spinal cord,
14:364;
SA93:#116
thigh,
SA95:#62
Travel
history
coccidioidomycosis,
SA95:#244
infections,
SA95:#244
Treacher
Collins
syndrome,
14:473
Trendelenberg
sign, 13:391
Tretinoin
(Retin-A),
15:47
Trichomonas
vaginalis,
I 4: 180
sexual
abuse,
I 3:443
vulvovaginitis,
14:141
Trichuriasis
associated
conditions,
SA95:#282
rectal prolapse,
SA95:#282
Tricyclic
antidepressants.
13:273;
14:41 1
attentional
disorders,
15:5
overdose,
15:151
Triglycerides
medium-chain,
15:233
content
in formulas,
SA95:#115
fat malabsorption,
SA95:#1
15
in preterm
infant,
14:123
Trimethoprim,
prophylaxis
of cystitis,
#255;
SA95:#134
Tuberculosis,
13:343;
14:263(abs);
16:223
atypical
disease,
l4:263(abs)
cervical
adenopathy,
15:276
evaluation,
SA94:#142,
#255
fever of unknown
origin,
15:127
spinal
cord,
14:364
transmission,
13:283
Tuberous
sclerosis,
characteristics,
SA94:#285
Tularemia,
cervical
adenopathy,
15:276
Tumors
neck,
15:276
skin, 13:371
spinal cord,
14:364
testes,
15:272
Turner
syndrome,
13:43
delayed
puberty,
SA95:#82
intelligence,
SA95:#236
karyotypes,
SA93:#208
language
development,
SA95:#236
Tympanic
membrane,
hyperemia
and
crying,
SA95:#277
Tympanocentesis,
otitis media,
14:320; SA94:#258
Tympanogram,
otitis media,
14:320
Tympanometry,
SA93:#1 3
hearing
disorders,
14:43
medical
record
review,
13:355
Tympanostomy
tubes,
I 3:23, 355
complications,
SA94:#269
indications,
SA94:#291
15:377
Trimethopri
16:22
S
S
Trisomy
2 1 I 4:488(abs)
atlantoaxial
dislocation,
tachypnea
of the newborn,
I 6:209
Transillumination
fiberoptic.
for arteries
and veins,
I 3:239(abs)
sinusitis,
14:345
Transition
to adulthood,
chronic
physical
disorders,
13:224
Transplantation,
liver,
14:436;
SA93:#1
.
m-sulfamethoxazole,
U
Ulcerative
colitis,
14:475
endoscopy,
14:352
laboratory
evaluation,
SA94:#59
treatment,
SA93:#1 6
Ulcers,
peptic.
16:257
Ultrasonography.
I 6:22
abdominal
pain, 14:302
appendicitis.
I 3:49(abs)
neurodiagnosis.
I 3:248
512
of the hips, 16:299
pancreatitis,
I 3:32(abs)
pelvic, 13:216
prenatal,
uses, SA93:#54
testicular
torsion,
13:295
Umbilical
catheterization,
use of
mannequins
in training.
13:244
Umbilical
cord care, 13:262
Umbilicus,
16:363
Pediatrics
Undescended
testicles,
Upper
respiratory
tract
15:272,
286
infections,
15: 185
fever,
15:127
transmission,
13:283
Urea cycle
defects,
characteristics,
disorders,
15:359
i,i
Review
Vol.
/6
No.
SA95:#21
/2
December
9
/995
I
45,
I
Ureteral
obstruction,
following
diuretic
therapy,
SA94:#109
Ureterocele,
16:117
urinary
tract obstruction,
SA95:#1 94
Ureteropelvic
obstruction,
16:223
Urethral
mass,
16:117
narrowing,
urinary
tract infection,
Urinary
tract infection,
16:22
cystitis.
16:190
incontinence,
SA95:#274
laboratory
diagnosis,
14:251;
SA93:#1 41
microbiology,
SA93:#255;
SA95:#242
obstruction,
ureterocele,
SA95:#1 94
prophylaxis,
I 5:377
radiologic
evaluation,
SA95:#1 76
recurrent,
reflux,
SA93:#31
1
SA94:#194
stricture,
trauma,
SA95:#213
valves
evaluation,
SA95:#274
posterior,
SA93:#81
Urethritis,
14:180
Urinary
ketones,
15:137
lithiasis,
15:495
retention,
16:117
Urinary
tract, obstruction
of upper,
16:223
screening
tests,
SA93:#141
specimen
for culture,
SA94:#209
treatment,
SA93:#269
Urinary
tract obstruction,
16: 1 17
Urination,
in newborn,
13:262
Urine
drug testing,
13:314;
SA93:#12
excretion
studies,
SA95:#287
first void, in newborn,
15:3 19(abs)
orange
color, rifampin,
1 3:354(abs)
Urologic
problems,
myelomeningocele,
13:293(abs)
Urticaria,
13:387;
16:178
cold, 15:289
insect sting, SA93:#218
papular.
SA94:#284
pigmentosa,
SA94:#50
mimicking
bruising,
14:215
transfusions,
I 5: 1 22(abs)
treatment,
SA95:#1 47
Usher syndrome,
hearing
disorders,
14:43
Uterine
bleeding,
dysfunctional,
treatment,
SA95:#1 47
Uteroplacental
insufficiency,
I 3:262
Uveitis,
16:203,
Uvula,
bifid,
14: 191
477
submucous
cleft
palate,
V
Vaccine
Varices,
administration,
15:400,
433
diphtheria-tetanus
toxoids
with
pertussis,
13:98; SA93:#125,
#201, #221
egg allergy,
14:245(abs)
Haemophilus
infiuenzae,
I 3:98
hepatitis.
13:203,
245
hepatitis
B, 13:203
influenza,
13:98; SA93:#68
meningococcal,
13:98; SA94:#150
pertussis,
13:98
pneumococcal,
13:98; SA93:#276
polio, SA95:#46
rubella,
13:98;
16:432(abs)
Vaginal
bleeding,
14:141
discharge,
13:443;
14:141
Vaginitis,
14:180
Vaginosis,
I 3:443
Valium,
febrile
seizures,
13:298
Valproic
acid, 13:364;
15:367(abs)
Vancomycin,
13:413;
16:83, 357(abs)
mechanism
of action,
I 5:440
Vanillylmandelic
acid,
neuroblastoma,
15:391
Varicella,
16:266,
283
SA95:#1 62
Varicocele,
SA95:#272
Vascular
access,
intraosseous,
I 5:157
malformation,
I 5:266
Vasculitis
hemiparesis,
evaluation,
SA95:#45
Henoch-Schoenlein
purpura,
13:130
purpura,
14:215;
SA95:#165
Vasopressin,
diabetes
insipidus,
I5:201
VATER
association,
15:338;
Vectors,
for arboviruses,
SA94:#231
Velopharyngeal
insufficiency,
16:17;
SA95:#1 90
Venereal
warts,
perinatal
acyclovir,
transmission,
I 5:23(abs),
in
Review
Vol.
/6
No.
12
characteristics,
SA95:#21
Venom
immunotherapy,
16:355(abs)
Venous
access,
peripheral,
15:157
hum, SA93:#19
Ventilation,
tube insertion,
14:320
Ventricular
tachycardia,
15:437
Ventriculitis,
14:1 I ; SA94:#236
Ventriculoperitoneal
shunt,
malfunction,
13:295
Verapamil,
arrhythmia,
15:437
Vermont
Children’s
Forum,
13:64
Vertigo,
15:1 15, 369; SA93:#170;
SA94:#235
benign
paroxysmal,
15:369
Very-low-birthweight
infants,
14:123;
16:3 16
Vesicoureteral
reflux,
16:22,
190;
SA93:#31
1
253(commentary)
exposure,
l5:254(abs);
SA93:#234
glucocorticoids,
16:266
herpesvirus,
13:107
immune
globulin,
15:254(abs);
SA93:#1 01
immunocompromised,
SA93:#1 00
shingles,
13:107,
283; SA93:#234
transmission,
16:283
Pediatrics
esophageal,
December
/995
indications
for surgery,
SA95:#93
management,
SA95:#93
Violence,
13:144;
15:16;
16:243
Viral infections,
development
of
specific
immunity.
SA93:#214
Viral pathogens
and transfusions,
I 5:246(abs)
Virotoxic
E coli, 14:2 18
Viruses,
laboratory
identification,
14:251
Visceral
larva migrans,
16:433
Vision,
retinopathy
of prematurity,
16:50
Visitation
rights,
16:306
Visual
impairment,
l6:77(abs)
dyslexia,
13:231
Vitamin
A, 13:364;
16:358(abs)
Vitamin
B,2, deficiency.
SA93:#74
Vitamin
D, 14:265
daily requirements,
in infants,
SA93:#21 5
Vitamin
E
deficiency,
SA94:#286
function,
SA94:#1 05
in preterm
infant,
14:123
Vitamin
K, 13:262;
14:265
deficiency.
SA94:#1 22
in newborn,
14:191
Vitamins,
13:185;
15:321
in formulas,
16:107
in preterm
infant, 14:123
Vitiligo,
16:365
Addison
disease,
Vocal cord
lesions,
evaluation,
nodules,
SA94:#1
paralysis,
13:435
SA93:#246
96
16:69
5/3
I:
.
:
.
, .
#{149}.
S
Volvulus,
13:50;
15:338
due to Meckel
diverticulum,
Vomiting.
15:24; SA93:#110
bilious
Hirschsprung
disease,
16:5
Meckel
diverticulum,
in infant,
SA93:#110
#{149}
gastroesophageal
15:289
15:289;
in newborn.
.
reflux.
I 3:174
.
#{149}
S
von Recklinghausen
disease,
14:433
von Willebrand
disease.
13:163
Vulvovaginitis.
14:141
group
A streptococcal.
SA94:#153
13:262
intussusception.
I 3:391
meningitis.
I 4: 155
recurrent,
etiologies.
SA93:#71
von Gierke
disease,
SA94:#24
prepubertal,
SA94:#1
53
15:289
w
Walkers,
infant,
SA95:#1 73
Warts,
13:371
venereal,
perinatal
transmission,
SA95:#21
Water
intoxication,
14:1 1, 103
Weakness
Addison
disease,
13:435
botulism,
14:117
exercise
intolerance.
I 3 :474(abs)
Guillain-Barr#{233} syndrome.
13:113
muscular
dystrophy,
16:437(abs)
myasthenia
gravis.
14:361
of lower extremities,
causes.
SA95:#89
Wechsler
Intelligence
Test. I 3:23 1;
16:338
Weight
Wilson
gain.
in infant,
loss,
SA93:#223,
#315
16:370
sports.
14:424
West syndrome,
SA94:#29
Western
blot, HIV. 14:38(abs)
Wheezing
asthma,
13:403
congestive
heart failure,
14:36
localized,
SA93:#285
Whey,
in formulas,
16:107
‘Whiff’
test, I 4: 141
Wiedemann-Beckwith
syndrome.
‘
1
‘
16:433
Wilms
tumor,
13:25:
disease,
14:436;
15:233
WISC-R
test. 16:325,
338
Wiskott-Aldrich
syndrome.
14:226
Woodcock-Johnson
Psychoeducational
Battery-R.
16:325,
338
Wounds
13:88
14:169
bite,
cat,
bite.
human.
SA93:#243
SA93:#1
79
care. 13:257
facial, SA93:#36
management.
tetanus
prophylaxis.
SA93:#125;
SA94:#271
Wide Range
Achievement
Test,
Revised
(WRAT-3),
16:325,
338
Writing
reversals,
dyslexia.
13:231
x
Xeroderma
pigmentosa.
16:365
Xerophthalmia,
13: 185
X-Iinked
recessive
disorders,
I 3: 138
Y
Yersinia
(‘llt(’rO(Oliti(’(l
Crohn-like
treatment,
disease.
SA95:#1
SA94:#226
45
z
Zelweger
Zidovudine.
syndrome.
14:371
15:359
Zinc
content
deficiency.
514
in formulas,
14:123:
Zipper.
release
Zoster
immune
SA93:#1 01
SA94:#119
16:352(abs)
Pediatrics
in Reviess
Vol.
of foreskin,
globulin,
16
No.
12
14:140
15:254(abs):
l)eee,nber
/995
TAL
tLt7WV
Pediatrics
of Own.rshlp,
M.nag.mnt,
amuc.s.’
101119h
t- 61Itnr
I
Point
j
12
s
p
3.1g95
It
I’ ‘
Monthly
Northwest
P
and Circulation
u.
I
In Review
4
141
-I.4$.
*1S75.
Ststm.nt
UNtTEDSTTES
PosThLsERvIcE..
17
p*_
II. B-1-I.
21175
5TM
Pediatrics
In Review
Seoteiiber
a
County
flk Grove Village.
Pediatrics
Cook County
Blvd
Elk Grove
c....
n.Qn
iitac
PNNN.N.N.CaN.
0
p
‘-
coo1(
B’vd
1995
a.....
D...,p....m.,
‘I.
a N.
$105
1L11N.
‘3 P*’NN.N
geN..s.Is.m.asws
11
60009-0927
26. 749
27.866
26.749
27,866
a
,..euan,aw’2v
American
141
Acadny
Northwest
of
Point
Village,
IL
60009-0927
a N.’NM
(3
0
0
I
0
0
,n..,fsN.e,k.w,3e
0
0
C..N.N.5
WN.PaSS
#{163}wee
C.
Ww
American
Acadeny
of Pediatrics
141 Northwest
Point Blvd
II
School of Medicine
and Dentistry
60009-0927
S
Robert
J. Haggerty,
MD.FMP
University
of Rochester
Martha
H. Saltzman
American
Acadeny
Cook County
Elk Grove Village.
S
601 Elmwood
Ave
Rechester.
NY
14642
(.)oIaL..s#{149}N.
141 Northwest
Point
Elk Grove Village.
of Pediatrics
Blvd
IL 60009-0927
7,211
(non-profit
s*cto
Revenue
of Pediatrics
organization
t1
Code.)
(r)
1)
of
141
Northwest
Point
Blvd
,.
0
Elk Grove
Village.
IL
I.t?al
60009-0927
41
.-fl&.t1’tL_.
Editor
October
3.1995
I..wpuN.PaN.N...aN...I#{243},.aa.m..a.N,
Instructions
FNNN.
100%
TN.CN.*NNSNN.dNN.
,,
under
th.a
34,145
100%
c_I_
Academy
0
33.960
W
Mierican
6.279
0
I2,.N...*sws
,o w
w,
27.866
26.749
N
ON...
to Publishira
,
biSo.sOcbs’
I
__________________
2
Nim
5N
N.NN IO’d
a.a.s.a.ee
“N..
0.
ANoaj
ms*vs.sv..
e.deoia......o.y
e.daasss
..o,a..e..eeN.w.9co.,..N...
aNi9sa. OiS
S.
N NScaNOaMdN.OA1dI
C..c&e’
S
,t
en..
I.
a
a NN.N.
.$‘aa’a
N.accpp
SN
.N”SOINSPN.IOI’
ISOcN.ONS.%’OO.n
a. *.
ii. a,......
CNPO’ONN.
IN.d
pS’N.S
#{248}c5NN.. Us.s
mo,sPi
i..a
i5St
i
3
4
N.,.
F’N.N.OnNNNSN
..v..agi...a..agas’p’MacaN...
‘ININ.N.P.S
a..a
&
pa
as
...,
w’
ya
p..
SPIN.
ISNIsaN.W
mOc$obS’
SNSS.,N.a&O..WN.
C O.’.s.’5.
N.ou
bs
St
N5SN.t
a
N’dt
N.
p..pi’
pN.t
C
%N.NaoS..d..NnsPN..a..
Fa*va
n..
0
t*MN.
PS
P5N...3$2&
..
‘...352
N...pe,a
ou....
‘..a
N.
,N.
This
One
IHIIIIIIIIIHIII
III II111111
IIII I1111
IIIII
AP82-EXX-ZKBU.
Pediatrics
iii
Review
t)l.
/6
No.
/2
1)eeeinbe,
I 995
.
.
....
515
.
Ani’i-iciii
z\cadcmv
of Ik’dRltFiC ‘S
Continuing
Programs
Spring
Education
Session
Annual
(‘hicss.o.
lIIinos
.\pril
I 3- I 7. I
Pediatric
July
UPDATE
1995-June
Selected
.
Meeting
I30”tOfl.
MaschuetI.
October
26-30.
Audio
996
Tapes
1996
15)1)55:’. ticlude:
.
I )uLgnosl
.
Misiiiiiallv
and
.
(rinar
N1uitte,iient
lnaie
Tract
1(1 enroll
U1DATE.
call
or write:
tPl)ATE
2 Sesview
Port
1)crniatulugv
lnleciioii
in Pediatric
Pedistric
ii Pediatric
Surgery
Blvd.
Vs’ssliington.
N ‘s I I 050-46
15
500/547-0055
Continuing
Education
Pediatric
Medical
Courses
I tpdate
Pediatrics
Vsilliaiiihtirg.
\irginia
l)eceniher
S
(‘urrent
Jantiir
I I - I 4.
Ne
in Pediatric’.
State-ut-the-Art
1996
1)irection
.\ruonio.
fl Pediatrics
I -:.
PREP:
\lril
I
7
.\nicrican
P()
Ho.
Elk (;re
R)/4.-90l6
I 9-2
New
York
I . I 996
Advances
Fe.
Ne
Mexico
274)ctoher
Philadelphia.
No
)rcvon
\cadeiu
..\pril
Septeniher
I 99(
eiiiher
Kaiisas
For further iiiloriiiation.
:i!LSC
York.
COURSE
I 2. I 996
(
9%
Nslay I7- 19. I996
I 996
IIc. reiiiiese’
Port luid.
: #{149}-
SS._5
Pediatrics
Nev
Santa
THE
I 2-- I 9.
Nili
5-U).
Pediatric
1exis
Fehruar
Juiie
March
Colorado
55
Florida
I 995
(‘oncept’.
Vail.
Sui
.-I 0.
I 996
Orlando.
2.
Pennsvl
I - 6.
1996
vania
I 996
‘s1 i..ouri
(liv.
contact:
ol Pediatrics.
,--
(N1F
2
-
-
-:
‘2!
Regixtration
927
Village. II.60009-0927
or 705/225-5005
Tlicc
feature
ctirrictiltii#{236}i. ( rcdit.
earned
‘.uhject
iiia5
niatter
coordinated
he ‘l’P1 ted t()
ard
ith the
the
PREP
PR IP
Education
:il1IJ!
aid.
v
5.’
I
r-
)“
I
.Jtj
L-!’
#{149}_r
P.S:4!!!
!
S